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Older people are frequent users 
of drugs with sedative properties 
although they are susceptible to 
adverse drug events. Sedative load 
refers to cumulative exposure 
to multiple drugs with sedative 
properties. This thesis investigated 
sedative load and adverse drug 
events including impaired mobility 
and muscle strength, and an 
increased risk of death among 
community-dwelling older people 
aged 75 years and older.
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ABSTRACT 
 
Older people are frequent users of drugs with sedative properties. However, older people 
are susceptible to adverse drug events. Sedative drug use has been associated with 
impaired physical and cognitive function, an increased risk of falls and increased mortality. 
Sedative load refers to cumulative exposure to multiple drugs with sedative properties. 
This thesis aimed to investigate sedative load and adverse drug events among 
community-dwelling people aged ≥75 years. The thesis had focus on (I) the prevalence and 
factors associated with sedative load, (II) the association between the sedative load and 
balance and mobility, (III) the association between sedative load and muscle strength; and 
(IV) evolution of sedative load over time and the corresponding risk of death. 
The study analyzed data from Geriatric Multidisciplinary Strategy for the Good Care of 
the Elderly (GeMS) study which was a prospective population-based, randomized 
comparative study conducted from 2004–2007 in Kuopio, Finland. Participants were 
randomized to the intervention (n=500) and comparison groups (n=500). All participants 
were interviewed annually by trained nurses regarding drug use, medical conditions, and 
other health-related factors. Physical function tests were conducted by trained 
physiotherapists. Data on mortality were extracted from national registers. Community-
dwelling persons (n=700 at baseline) were included in the analyses. Sedative load was 
calculated for each participant according to a previously published model. Unadjusted and 
adjusted analyses were conducted using logistic regression, analysis of covariance 
(ANCOVA) and Cox proportional hazards models.  
At the baseline of the GeMS Study, 29% of participants used one or more sedative drugs 
on regular basis. Factors associated with higher sedative load were female sex, poor self-
rated health, impaired Instrumental Activities of Daily Living, and subjective feelings of 
loneliness. Sedative load was associated with poorer performance in balance and mobility 
tests which included 10 meter walking speed, the Timed Up and Go test and Berg Balance 
Scale. Sedative load was not associated with self-reported ability to walk 400 meters. 
Sedative load was associated with poorer performance in muscle strength tests, including 
hand grip strength, knee extension strength and chair stands test. Increasing sedative load 
was associated with poorer grip strength. Sedative load increased during the 3-year follow-
up, and at the end of study, 36% of participants used sedative drugs. However, increasing 
sedative load was not associated with an increased risk of death. 
In conclusion, cumulative exposure to drugs with sedative properties was associated 
with decreased physical function. This represents a threat to independent living among 
older people. This thesis highlights the importance of implementing strategies to optimize 
sedative drug use among older people. 
 
National Library of Medical Classification: QV 85, WE 103, WE 500, WT 166 
Medical Subject Headings: Hypnotics and sedatives/adverse effects; Prevalence; Drug Utilization; Postural 
Balance; Movement; Muscle strength; Mortality; Aged 
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TIIVISTELMÄ 
 
Sedatiivien eli väsyttävien lääkkeiden tai väsyttävän sivuvaikutuksen omaavien lääkkeiden 
käyttö on yleistä iäkkäillä, vaikka niiden käyttöön liittyy heillä haittatapahtumia useammin 
kuin nuoremmilla ihmisillä. Tässä tutkimuksessa käytettiin aiemmin kehitettyä mallia, 
jonka avulla voidaan arvioida kokonaislääkityksen sedatiivisuus, eli sedatiivikuorma. 
Väitöskirjan tavoitteena oli tutkia lääkityksen sedatiivikuormaa ja siihen liittyviä 
haittatapahtumia kotona asuvilla yli 75-vuotialla henkilöillä. Tavoitteena oli tutkia (I) 
sedatiivikuorman esiintyvyyttä ja siihen liittyviä tekijöitä, (II) sedatiivikuorman yhteyttä 
tasapainoon ja liikkumiskykyyn, (III) sedatiivikuorman yhteyttä lihasvoimaan, ja (IV) 
sedatiivikuorman muuttumista kolmen vuoden seurantajakson aikana, sekä siihen liittyvää 
kuolleisuutta. 
Tutkimuksessa käytettiin väestöpohjaisessa Hyvän Hoidon Strategia (HHS) 
tutkimuksessa kerättyä aineistoa. HHS-tutkimukseen valittiin tuhat 75-vuotiasta ja sitä 
vanhempaa kuopiolaista, jotka satunnaistettiin interventio- (n=500) ja verrokkiryhmään 
(n=500). Tähän tutkimukseen poimittiin aineistosta kotona asuvat iäkkäät, joita oli 
tutkimuksen alkaessa 700 henkilöä. Tutkimushoitajat haastattelivat tutkittavat vuosittain 
(2004-2007) terveydentilan ja lääkkeiden käytön suhteen. Fysioterapeutit testasivat 
tutkittavien liikkumiskykyä, lihasvoimaa ja tasapainoa. Sedatiivikuorma laskettiin aiemmin 
julkaistun mallin mukaan jokaiselle tutkittavalle. Haittatapahtumien yhteyttä sedatiivi-
kuormaan tutkitiin logistisen regression, kovarianssianalyysin ja Coxin mallin avulla. 
Tutkimuksen alussa 29 prosenttia tutkittavista käytti yhtä tai useampaa väsyttävää 
lääkettä säännöllisesti. Sedatiivien käyttäjät olivat useammin naisia ja he kokivat 
terveydentilansa huonoksi verrattuna henkilöihin, jotka eivät käyttäneet sedatiiveja. Lisäksi 
sedatiivien käyttöön liittyi heikentynyt välineellisistä päivittäisistä toiminnoista 
selviytyminen, sekä subjektiivinen yksinäisyyden tunne. Sedatiivikuorman todettiin olevan 
yhteydessä heikentyneeseen liikkumiskykyyn ja tasapainoon testeissä, joihin kuuluivat 10 
metrin kävelynopeus, Timed Up and Go –testi sekä Bergin tasapainotesti. Sedatiivikuorma 
oli yhteydessä heikentyneeseen lihasvoimaan, jota mitattiin käden puristusvoimalla, polven 
ojennusvoimana sekä viiteen tuolilta ylösnousuun käytetyllä ajalla. Mitä suurempi oli 
sedatiivikuorma, sitä huonompi oli käden puristusvoima. Sedatiivikuorma kasvoi 
kolmevuotisen seuranta-ajan kuluessa, ja tutkimuksen lopussa 36 prosenttia tutkittavista 
käytti väsyttäviä lääkkeitä. Sedatiivikuorma ei kuitenkaan ollut yhteydessä suuren-
tuneeseen kuoleman riskiin. 
Johtopäätöksenä todetaan että altistuminen väsyttäville lääkkeille on yhteydessä 
heikentyneeseen fyysiseen suorituskykyyn. Tämä voi muodustua uhaksi itsenäiselle 
elämiselle, jossa vaaditaan suoriutumista jokapäiväisistä toiminnoista. Tutkimuksen 
tulokset korostavat säännöllisen lääkkeiden käytön arvioinnin merkitystä, sekä uusien 
menetelmien tarvetta lääkehoidon hyötyjen ja haittojen arviointiin. 
 
Luokitus: QV 85, WE 103, WE 500, WT 166 
Yleinen Suomalainen asiasanasto: lääkkeet; sedatiivit; esiintyvyys; käyttö; haitat; tasapaino; liikuntakyky; 
lihasvoima; kuolleisuus; ikääntyneet 
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Definitions of key terms 
 
Adverse drug event (ADE) 
Adverse drug event is an unintended incident due to a medication which causes harm to a 
patient. 
 
Adverse drug reaction (ADR) 
Adverse drug reaction is a noxious and unintended response to a drug at doses normally 
used. Adverse drug reactions are a type of adverse drug event resulting from the side effect 
of a drug. 
 
Community-dwelling 
This term is used when considering older persons who are not in assisted living facilities 
(including self-care retirement villages, residential aged care facilities, nursing homes, long-
term care facilities, hospitals, or other types of institutional accommodations). 
 
Older person 
In the literature review, the main rule is that older persons are those aged ≥65 years. 
However, some of the included studies defined older persons as aged ≥60 years. In 
methods and results, older people are persons aged ≥75 years. 
 
Sedation 
Sedation refers to the objectively measured decreased psychomotor functioning and 
subjective feelings of drowsiness and sleepiness. 
 
Sedative drugs 
This term is used when referring to all drugs contributing to sedative load and thus, 
possessing sedative properties.  
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1 Introduction  
Sedation is defined as subjective feelings of drowsiness and sleepiness, and also as 
objectively measured slowing of psychomotor functioning (Bourin et al. 2004). An 
example of declined psychomotor functioning is increased reaction time. Aging is 
associated with various changes in pharmacodynamics and pharmacokinetics of drugs 
(Turnheim 2003, McLachlan et al. 2009). One important age-related change is an increased 
susceptibility to sedative effects of drugs which results in more pronounced effects of 
drugs among older people (Bowie et al. 2007). Because drugs exert sedative effects through 
multiple pharmacological mechanisms, methods to quantify the effect of taking multiple 
drugs with sedative properties have been developed (Taipale et al. 2010). 
Sedative load refers to cumulative exposure to drugs with sedative properties 
(Linjakumpu et al. 2003). It takes account on both drugs prescribed for intentional sedation 
and drugs used for somatic disorders which possess sedation as a prominent side effect. 
Models that take into account use of multiple drugs are important because older people 
often use multiple sedative drugs (Linjakumpu et al. 2004). Among community-dwelling 
older people in Finland in 19981999, 35% used one or more drugs with sedative 
properties.  
Sedative drugs have been associated with various adverse drug events (ADEs) among 
older users. These include cognitive decline (Wright et al. 2009), impaired balance (Cutson 
et al. 1997), decreased mobility and muscle strength (Lord et al. 1995, Gray et al. 2006), and 
an increased risk of death (Mittal et al. 2011). One important ADE is an increased risk of 
falls and fractures (Cumming and Le Couteur 2003, Hartikainen et al. 2007). Falls and 
fractures are a threat to independent living among older people because of their 
potentially hazardous consequences on physical function. Decreased mobility, balance and 
muscle strength may increase the risk of falls (Lajoie et al. 2002, Moreland et al. 2004, 
Cooper et al. 2011). Furthermore, mobility is essential for performing daily activities.  
Adverse drug events related to sedative and psychotropic drug use have primarily been 
investigated in pharmacoepidemiological studies. Randomized controlled trials (RCTs) are 
considered as ‘gold standard’ when assessing the efficacy of drugs. However, older people 
are often excluded from participation in RCTs (Hilmer et al. 2012). Although 
recommended, ADEs are often not monitored and not tested specifically among older 
people. Reasons for not including older persons in these trials are that they often have 
multiple comorbidities and polypharmacy. In addition, RCTs are often of short duration, 
include small number of participants and participants in both intervention and control 
arms may receive more intensive care than real-life patients (Hilmer et al. 2012). Thus, 
pharmacoepidemiological studies are needed to study ADEs in large populations that 
include a broader range of patients, treated according to real-life conditions. 
The frequent use of sedative drugs and corresponding ADEs are a major public health 
concern. The proportion of Finns aged ≥75 years is increasing rapidly (Statistics Finland 
2011). The number of Finns aged 75 years or older will double from 437,000 in 2010 to 
847,000 in 2030. Thus, the appropriate care of older people and maintenance of active and 
independent living is increasingly important. One of the main goals of the Finnish health 
policy is that older people should be able to live independently in their own homes as long 
as possible (Ministry of Social Affairs 2008). This goal implies that the maintenance of 
2 
 
 
physical function is crucial because impaired physical function is often associated with 
loss of independence.  
The purpose of this thesis was to investigate sedative load and ADEs among 
community-dwelling older people. These ADEs included decreased balance, mobility and 
muscle strength, and risk of death. 
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2 Review of the literature 
The scope of this literature review was the sedative effects of drugs and methods used to 
measure these effects among older persons. Furthermore, the epidemiology of sedative 
drug use and corresponding adverse events were also reviewed. Adverse events included 
in the review were mobility, muscle strength, balance and mortality.  
2.1 SEDATION 
2.1.1 Definition and measurement 
Sedation refers to the objectively measured decreased psychomotor functioning and 
subjective feelings of drowsiness and sleepiness (Buffett-Jerrott et al. 2002, Bourin et al. 
2004). In the broadest sense, sedation may refer to impairments in cognitive processing 
including memory and attention deficits (Buffett-Jerrott et al. 2002). Both subjective and 
objective measures of sedation are important although they do not necessarily correlate 
with each other. A person may not report or feel sedated but may show psychomotor 
slowing in an objective test (Echizenya et al. 2007).  
Subjective assessment of sedation is often undertaken using visual analogue scales 
(Bourin et al. 2002). In the test, a participant indicates feelings by placing a mark on an 
ungraded line with opposite descriptive statements at each end (for example, calmness 
versus agitation). Scores are measured as a distance from a line indicating the “normal” 
situation. Objective measurement of sedation is conducted using psychometric tests which 
measure different aspects of sensory-motor processing, cognitive skills, concentration, and 
psychomotor and motor abilities (Hindmarch 2009). Measurement of reaction time is an 
example of a typical psychometric test (Bourin et al. 2004). Reaction time may be tested as 
the time taken to start a previously decided action (like pressing a button), or as choice 
reaction time in which participants have to choose the right action based on the stimulus 
(for example, press one of six buttons based on which is illuminated). Another widely 
used psychomotor test is the Digit Symbol Substitution Task (DSST) (Weingartner et al. 
1995, Hege et al. 1997, Buffett-Jerrott et al. 2002, Wezenberg et al. 2007) which has been 
used among older people (Hilmer et al. 2007). In the test, participants learn a code in 
which symbols are paired with the digits 1 through 9 (Buffett-Jerrott et al. 2002). 
Participants are asked to copy the symbols associated with each digit, in the order 
presented, as quickly and accurately as possible. The DSST has been shown to measure 
drug effects, for example slowing after a dose of benzodiazepine (Wittenborn 1979) but it 
also requires memory and learning abilities which may limit the use among older people 
with cognitive decline.  
For many years, sedation was considered as an essential component of the therapeutic 
effect of antipsychotics and antidepressants (Bourin et al. 2004). Introduction of atypical 
antipsychotics and selective serotonin reuptake inhibitors (SSRIs) challenged this belief 
because of having equal therapeutic effect while demonstrating considerably less sedation. 
Since then, sedation associated with drug use has been studied further, and is now 
considered an undesirable adverse effect. Sedation is no longer considered useful in the 
treatment of agitated patients with depression (Majeroni 1998). Nowadays, the 
maintenance of an active lifestyle is favored and considered important for the recovery 
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process from depression (Bourin et al. 2004). Sedation is a particularly unwanted effect in 
diseases or syndromes that impair cognition and psychomotor functioning, for example 
severe depression and dementia (Hindmarch 2009). Cognitive decline is another example 
in which efforts are made to maintain the current cognitive capacity and thus, use of drugs 
counteracting this objective should be avoided.  
2.1.2 Pharmacology of sedative effects of drugs 
Sedation is mediated by multiple pharmacological mechanisms in the central nervous 
system (CNS). Sedative effects of drugs mediated by agonism of the benzodiazepine 
receptor in GABA-A complex are well-known (Buffett-Jerrott et al. 2002, Bourin et al. 2004, 
Möhler et al. 2002). Benzodiazepines and barbiturates induce sedation through this 
mechanism. Subtypes of GABA-A receptor also mediate other effects of benzodiazepines, 
including anterograde amnesia, attentional impairments, anticonvulsant effects, muscle 
relaxation and anxiolytic effects (Möhler et al. 2002). Benzodiazepine use has been 
associated with various ADEs including impaired cognition, psychomotor skills, memory 
and driving performance among older people (Verster et al. 2007). 
Sedative effects of the first generation antihistamines are mediated by antagonism of 
histamine H1 receptors in the CNS (Timmerman 1999, Brown et al. 2001, Bourin et al. 2004, 
Turner et al. 2006). Sedative effects of histamine antagonism may be explained with the 
fact that histamine regulates the sleep-wake cycle (Tiligada et al. 2011). First generation 
antihistamines may also cause marked adverse events other than sedation, including 
memory impairment which may be related to their effects on cholinergic and 
monoaminergic systems (Turner et al. 2006). Many psychotropic drugs including 
antipsychotics, tricyclic antidepressants and second generation antidepressants, also bind 
to H1 receptors which contributes to their sedative potential (Bourin et al. 2004, Tiligada et 
al. 2011).  
Opioids bind to μ-opioid receptors which also mediate sedation (Young-McCauhgan et 
al. 2001). Opioid-induced sedation has been proposed to be a unique, disordered level of 
consciousness in which arousal and content processing abilities are affected. This 
manifests in decreased wakefulness and slowed interpretation of the environment. 
 A potential source of sedative effects of drugs is antagonism or agonism of α1- and α2-
adrenergic receptors in the CNS (Bourin et al. 2002, Reynolds 2004). Antagonism of α1-
adrenergic receptors has been used to explain sedative actions of conventional and 
atypical antipsychotic drugs (Reynolds 2004).  Antagonism of α1-receptors is also related 
to cardiac events including prolongation of QT interval and arrhythmias. Alpha2-receptor 
antagonism is proposed to be cause of sedative potential of mianserin together with H1-
antagonism (Bourin et al. 2002). However, antagonism of presynaptic α2-adrenergic 
autoreceptors on noradrenergic neurons enhances the synthesis and release of 
noradrenalin which is often referred as an activating mechanism of antidepressants 
(Ramaekers et al. 1998). Blockage of muscarinic receptors is also associated with sedative 
effects although this anticholinergic action results in many other adverse effects too 
(Bourin et al. 2002). There may also be other mechanisms or receptors which are involved 
in sedative and cognitive effects of drugs.  
2.1.3 Pharmacology of sedative effects on physical function 
The sedative effects of drugs may result in impaired physical function. Mechanisms 
behind this are not fully understood. It is likely that mechanisms leading to mobility 
limitation are multidimensional, and may be due to drug-related cognitive impairment, 
slowing of neuromuscular processing in the CNS, overall sedation, muscle-relaxant effects 
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and reduced muscle function (Hindmarch 1980, Davidoff 1989, Cutson et al. 1997, See et 
al. 2008, Hindmarch 2009).  
In his review of psychotropic drugs and associated psychomotor effects, Hindmarch 
concluded that slowing of motor activity and co-ordination has been associated with many 
drugs with sedative properties (Hindmarch 1980). In the review, motor performance was 
measured with various tests including simple tests like finger tapping test, as well as with 
assessment of co-ordination of sensory and motor systems in simulated car driving tasks 
and reaction time tests. The conclusion was that benzodiazepines were the most often 
studied drugs, and have been shown to impair performance in these tasks. Besides 
benzodiazepines, impairment in reaction time was also reported with diphenhydramine, 
amitriptyline and mianserin. The reviewed studies were conducted among healthy 
volunteers.  
All psychotropic drugs (antipsychotics, antidepressants and benzodiazepines) have 
been associated with impairments of cognitive function (Hindmarch 2009). Although 
mobility tasks like walking have been considered automatic they also require cognitive 
processing (Snijders et al. 2007). Thus, impaired cognitive function may lead to difficulties 
in walking, especially in an outdoor environment when there are many factors requiring 
attention. 
Muscle-relaxant properties of benzodiazepines and muscle relaxant drugs are one 
potential mechanism behind the impaired physical function (Davidoff 1989, See et al. 
2008). GABA-A receptors in motor neurons in spinal cord mediate muscle relaxant 
properties of benzodiazepines (Möhler et al. 2002). However, it has been stated that 
muscle relaxant effects requires higher doses of benzodiazepines than anxiolytic effects. 
The mechanism behind the impairment of physical function may also be related to 
neuromuscular processing and activation of muscles. Cutson and coworkers showed that 
diazepam delayed muscle activation during balance tests conducted among older people 
(Cutson et al. 1997). Rapid activation of muscles required to regain balance after a 
disturbation is essential for walking ability.  
2.1.4 Sedation and aging 
The sedative effects of drugs may be pronounced among older people due to age-related 
changes in organ function and body composition, leading to altered pharmacokinetics and 
pharmacodynamics (Turnheim 2003, McLachlan et al. 2009). Aging may be associated with 
reduced hepatic blood flow and a decline in liver mass that reduces drug metabolism. 
Declining renal function may cause an accumulation of drugs that are excreted via the 
kidneys. This may include drugs that undergo hepatic metabolism and then re-enter 
systematic circulation before being excreted as hydrophilic metabolites or conjugates. A 
reduction in lean body mass and an increase in the percentage of adipose tissue may result 
in an increased volume of distribution of lipophilic drugs, such as diazepam. These factors 
contribute to prolonged elimination half-lives of sedative drugs in older people compared 
to middle aged and younger people. 
Older people are more susceptible to sedative effects of drugs than younger people 
(Bowie et al. 2007). Mechanisms contributing to pharmacodynamic changes include 
altered neurotransmitters or their receptors, particularly reduction in dopamine and 
acetylcholine content in the brain (Turnheim 2003). Reduction in dopamine content 
predisposes aging brain to an increased frequency and severity of extrapyramidal 
symptoms related to antipsychotic drugs. One important factor is that with aging the 
blood-brain barrier becomes more permeable and drugs penetrate the CNS more readily 
(Bowie et al. 2007). It has been shown that activity of efflux pump protein p-glycoprotein 
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decreases and brain may be exposed to higher drug levels in older people (Toornvliet et al. 
2006). This is problematic because a serum concentration is not correlated with elevated 
drug level in the brain. In addition, decreased efflux properties also lead to prolonged 
residence time in the brain. Age-related changes have been observed in GABAA-
benzodiazepine receptor complex in relation to number of receptors and their subunit 
composition which possibly is associated with attenuated sedative effects of 
benzodiazepines (Turnheim 2003).  
Data on aging-related changes in pharmacokinetics and pharmacodynamics of drugs 
has been increasing during recent years (Turnheim 2003, Bowie et al. 2007, McLachlan et 
al. 2009). However, there are still limited data on sedative effects of drugs among older 
people. One reason is that older people are often excluded from clinical trials because of 
their multiple comorbidities and medications (Hilmer et al. 2011). Furthermore, clinical 
trials are often not powered to detect adverse functional outcomes, and functional 
outcomes are not often considered as adverse drug reactions (ADRs) in the clinical trials. 
2.2 METHODS TO QUANTIFY THE CUMULATIVE EFFECT OF TAKING 
MULTIPLE DRUGS WITH SEDATIVE PROPERTIES 
The premarketing clinical trials of drugs may not provide adequate information on drug 
response and ADEs among older people (Hilmer et al. 2011). In these RCTs, participants 
may receive more intensive care than in real-life settings, the number of participants is 
usually small and studies are often of limited duration. Thus, knowledge of ADEs specific 
to older people is often obtained in postmarketing studies utilizing 
pharmacoepidemiologic methods (Hilmer et al. 2011).  
Quantifying the cumulative effect of taking multiple drugs with sedative properties is 
complicated because drugs with sedative properties do not have a common 
pharmacology. Four methods to assess cumulative effect of taking multiple drugs with 
sedative properties have been developed and utilized in the research literature (Taipale et 
al. 2010). Each method has been developed for different purposes and thus, drugs 
included in the methods differ (Table 1).  
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Table 1. Comparison of the different methods to calculate cumulative effect of taking multiple 
drugs with sedative properties and ratings proposed to drug classes 
 
Drug class Sedative Load 
Model 
Sloane Model 
 
Drug Burden 
Indexa, b 
CNS Drug 
Modelb 
Conventional 
antipsychotics 
rating: 2 rating: 3 (except 
molindone rating 6) 
included included  
Atypical antipsychotics rating: 1 rating: 3 included included 
Tricyclic antidepressants 
and non-selective MAO 
inhibitors 
rating: 2 rating: 3 (except 
phenelzine rating 6) 
included included 
SSRIs rating: 1 rating: 3 included included 
Second generation 
antidepressants 
rating: 1 (except 
mianserin rating 2) 
rating: 3 included included 
Benzodiazepines rating: 2 rating: 6  included included 
Other anxiolytics and 
hypnotics (clometiazole, 
valerian, barbiturates, 
first generation 
antihistamines, buspiron, 
chloral hydrate) 
rating: 2 rating: 3 (except 
diphenhydramine 
and chloral hydrate 
rating 6) 
included not included 
Opioids rating: 1 rating: 3 included included 
Antiepileptics rating: 1 rating: 3 included not included 
Antiemetics 
(metoclopramide, 
scopolamine) 
rating: 1 rating: 3 included not included 
Antispasmodics with 
psychotropics 
rating: 1 no included not included 
Centrally acting muscle 
relaxants 
rating: 1 no included not included 
Anticholinergic anti-
parkinson drugs 
rating: 1 rating: 3 included not included 
Indomethacin (with 
ethylmorphine) 
rating: 1 rating: 3 not included not included 
Other drugs scored in a 
model 
Xanthines, 
antitussives with 
sedating 
components and 
antiemetics and 
drugs for dizziness 
incl. psychotropics, 
anticholinergic 
drops for eyes: 
rating 1 
donepezil, atenolol, 
clonidine, levodopa, 
doxazosin, 
terazosin, prazosin: 
rating 1 
wide range of 
other 
anticholinergic 
drugsa 
 
DBI = Drug Burden Index, CNS = central nervous system, MAO = monoamine oxidase, SSRIs = 
selective serotonin reuptake inhibitors. 
a Drugs with both anticholinergic and sedative properties are classified as anticholinergics.  
b The DBI and the CNS Drug Model do not include ratings of sedative drugs but consider only doses. 
Adapted according to Taipale et al. 2010 
 
2.2.1 Sedative Load Model 
The Sedative Load Model was developed by reviewing the summary of product 
characteristics for all drugs available in Finland from 1998 to 2001 (Linjakumpu et al. 
2003). The model was developed to represent a comprehensive classification of all drugs 
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on market and to include also drugs for somatic disorders. All drugs were classified into 1 
of 4 groups based on their sedative potential. The 4 groups were: (1) primary sedatives; (2) 
drugs with sedation as a prominent side effect or preparations with a sedating component; 
(3) drugs with sedation as a potential adverse effect; and (4) drugs with no known 
sedation. The classification was based on consensus between a psychogeriatrician, a 
geriatrician, and a physician specialized in pharmacoepidemiology. Each drug in group 1 
was assigned a sedative rating of 2, and each drug in group 2 was assigned a sedative 
rating of 1 (Linjakumpu et al. 2004). Drugs in groups 3 and 4 were not assigned a sedative 
rating. According to the model, sedative load was calculated by summing the sedative 
rating for each drug in a person’s medication regimen according to the following formula: 
 
 Sedative load =σ ܴܵ௞௡௞ୀଵ  
where n stands for the number of drugs and SRk indicates the sedative rating for drug k. 
2.2.2 Sloane Model 
Sloane et al. published an adaption of the Sedative Load Model (Sloane et al. 2008). Their 
objective was to develop a method to control for possible confounding caused by sedative 
and analgesic drug use in therapeutic trials. In the Sloane Model, group 3 from the 
Sedative Load Model (“drugs with sedation as a potential adverse effect”) was modified to 
become “drugs with sedation as a potential adverse effect that can persist beyond 
initiation of the drug.” Group 1 (“primary sedatives” in the sedative load model) was 
redefined to only include benzodiazepines, diphenhydramine, phenelzine, molindone, 
and chloral hydrate, and all other drugs were transferred to group 2 (ie, other 
conventional antipsychotics, tricyclic antidepressants, anxiolytics [such as hydroxyzine]). 
Sedative ratings of 6, 3, and 1 were assigned to groups 1, 2, and 3, respectively (instead of 
2, 1, and 0 in the Sedative Load Model). The adaption by Sloane et al. also considers the 
dose of each drug. According to the Sloane model, the cumulative effect of taking multiple 
drugs with sedative properties is calculated according to the formula: 
 
ܵܮ௜௝ ൌ ෍
ܦ௜௝௞ ൈ ܴܵ௞
ܣܦܯܦ௞
௠
௞ୀଵ
 
 
where SL is sedative load (for resident i on day j), D is daily dose for medication k (by 
resident i on day j), SR is sedative rating of medication k, and ADMD is average daily 
maintenance dose for drug k.    
2.2.3 Drug Burden Index 
The Drug Burden Index (DBI) was developed by Hilmer et al. to assess the possible impact 
of drug burden on physical and cognitive function among older people (Hilmer et al. 
2007). It was designed to be an evidence-based guide for prescribing in older people. The 
DBI considers both anticholinergic and sedative drug burden. Drugs that possess both 
anticholinergic and sedative properties are classified as anticholinergic drugs when 
calculating the DBI. The DBI was developed according to the principles of pharmacologic 
dose–response effect, and the model includes the doses of drugs. The DBI is covered by an 
international patent. Hilmer et al. defined total drug burden as the sum of anticholinergic 
and sedative burden according to the formula:   
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where E is the pharmacologic effect, α is the proportionality constant, D is the daily 
dose, and δ is the recommended minimum daily dose as approved by the US Food and 
Drug Administration. When the DBI has been used outside of the US other reference doses 
have been used. 
2.2.4 CNS drug model 
Hanlon et al. developed a model to investigate the relationship between use of CNS-active 
drugs and various adverse outcomes (Hanlon et al. 2009, Wright et al. 2009). According to 
this method, CNS drugs include opioid receptor agonists, benzodiazepine receptor 
agonists, antidepressants, and antipsychotics. The authors computed the overall CNS 
standardized daily dose by considering use of drugs from these drug groups. The 
following formula was used:  
ܵܦܦ ൌ
ܦ
ܯܧܦ
 
 
 
where the mean daily dose (D) of a CNS drug is converted to a summated standard 
daily dose (SDD) by dividing it with the minimum effective dose (MED) per day 
recommended for older people in the Geriatric Dosage Handbook: Including Clinical 
Recommendations and Monitoring Guidelines (Semla et al. 2007). The CNS standardized daily 
dose is the sum of the SDDs. 
2.3 USE OF PRIMARY SEDATIVES AND OTHER DRUGS WITH SEDATIVE 
PROPERTIES 
Few studies have been conducted specifically concerning the epidemiology of sedative 
load among older people. On the contrary, there are numerous epidemiological studies 
about the use of specific classes of sedative drugs and psychotropic drugs. The focus of 
this review was on the prevalence of sedative load and sedative drug use studied using 
one of the four methods to quantify cumulative exposure to sedative drugs.  
2.3.1 Epidemiology of sedative load 
The epidemiology of sedative load has been studied only in four studies (Table 2). Among 
community-dwelling Finns aged 64 years and older in 199899, 35% had sedative load ≥1, 
and 12% had a sedative load of ≥3 (Linjakumpu et al. 2004). Among residents with 
dementia living in residential aged care facilities in Northern Ireland in 20082010, 67% 
had a sedative load ≥1 and 12% had a sedative load of ≥3 (Parsons et al. 2011). Among 
residents of long-term care facilities in Helsinki, 85% had a sedative load ≥1 and 53% had a 
sedative load ≥3 in 2003 (Taipale et al. 2009). A study comparing sedative load between 
those with and without dementia in the same study population found that residents with 
and without dementia had a similar sedative load (mean 3.0 versus 2.7) (Bell et al. 2010).  
Factors associated with sedative load have been investigated in one study (Linjakumpu 
et al. 2004). Among community-dwelling Finns, older age (≥80 years) and female gender 
were associated with sedative load ≥3. Sociodemographic factors associated with sedative 
load included also education (less than primary school) and current smoking. Other 
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factors associated with sedative load were poor self-rated health, depression, dementia 
and mobility difficulties.  
 
Table 2. Prevalence of sedative drug use according to Sedative Load Model, Drug Burden Index, 
Sloane Model and CNS Drug Model 
  
Study, 
country 
Year N Age Setting Description of sedative drug use 
in the population 
Sedative load 
Linjakumpu 
et al. 2004 
Finland 
1998‒1999 1197 ≥64 years, 
57% women 
C 35% were users sedative drugs,  
12% had sedative load of ≥3 
Taipale et 
al. 2009 
Finland 
2003 1004 Mean age 81 
years, 75% 
women 
I 85% were users of sedative drugs,  
53% had sedative load of ≥3 
Bell et al. 
2010 
Finland 
2003 1052, 
781 with 
dementia 
 I Mean sedative load 3.0 among those 
with dementia, mean sedative load 
2.7 among those without dementia 
Parsons et 
al. 2011 
UK 
2008‒2010 115 Mean age 86 
years, 79% 
women 
I 67% were users of sedative drugs, 
12% had sedative load of ≥3 
Drug Burden Index 
Hilmer et 
al. 2007  
US, Health 
ABC study 
1997‒1998 3075 Age range 
7079 years, 
mean age 74 
years, 52% 
women 
C 14% were users of sedative drugs 
Cao et al. 
2008 
US, 
Women’s 
Health and 
Ageing 
Study 
1992 932 ≥65 years, 
median age 
78 years, 
100% women 
C 16% were users of sedative drugs, 
mean DBISED 0.37 among users 
Gnjidic et 
al. 2009  
Australia, 
Concord 
Health and 
Ageing in 
Men Project 
2005‒2007 1705 
 
≥70 years, 
mean age 77, 
100% men 
C Of users of medicines,  
13% were users of sedative drugs,  
mean DBISED 0.07, 
most common sedative drugs 
anxiolytics (5% using) 
Hilmer et 
al. 2009b 
US, Health 
ABC Study 
1997‒1998 
and 6 
years of 
follow-up 
2172 7079, 52% 
women  
C 34% were users of DBI drugs at 
baseline,  
26% were users of DBI drugs at year 
3,  
29% were users of DBI drugs at year 
5 
Wilson et 
al. 2010 
Australia 
 526 Mean age 86 
years, 72% 
women 
I 42% were users of sedative drugs; 
mean DBISED 0.33, most common 
sedative drugs were anxiolytics (18% 
using) 
Gnjidic et 
al. 2010 
Australia 
2008‒2009 115  I 23% exposed to sedative DBI drugs 
in intervention group and 29% 
exposed to sedative DBI drugs in 
control group 
Castelino et 
al. 2010 
Australia 
 372 Mean age 76 
years, 55% 
women 
C 61% were exposed to DBI drugs 
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Table 2. Continued 
 
    
Study, 
country 
Year N Age Setting Description of sedative drug use 
in the population 
Gnjidic et 
al. 2011a 
Finland, the 
GeMS 
Study 
2004 700 Mean age 82 
years (all 
≥75 years), 
69% women 
C 37% exposed to DBI drugs 
Gnjidic et 
al. 2011b 
Australia 
 
2008‒2009 115 Mean age 82 
years, 73% 
women 
I 26% were users of regular sedative 
drugs, mean DBISED 0.12 
Lowry et al. 
2011 
UK 
 362 Mean age 84 
years, 59% 
women 
I 41% were users of sedative drugs 
Gnjidic et 
al. 2012  
Australia, 
Concord 
Health and 
Ageing in 
Men Project 
2005‒2007, 
follow-up of 
2 years 
1662, 
156 frail 
 
≥70 years, 
mean age 77, 
100%  
men 
C 46% of frail participants were 
exposed to DBI drugs compared to 
20% of robust participants 
CNS Drug Model 
Wright et 
al. 2009  
US, Health 
ABC Study 
1997‒1998 2737 ≥65, 53% 
women 
CNS 
Drug 
Model 
14% were users of CNS drugs at 
baseline 
Boudreau 
et al. 2009 
and Hanlon 
et al. 2009, 
US, Health 
ABC Study 
1997‒1998 3055 70‒79,  
52% women  
CNS 
Drug 
Model 
14% were users of CNS drugs 
C=community-dwelling, I=institutional living (in long-term care facilities, residential aged care facilities, 
self-care retirement villages), DBI = Drug Burden Index, DBISED = sedative component of Drug Burden 
Index, CNS = central nervous system, HR= hazards ratio, Health ABC = Healthy, Aging and Body 
Composition 
 
2.3.2 Epidemiology of sedative use according to other models 
The only study utilizing the Sloane model included data on 90 institutionalized patients of 
a clinical trial and all of them were users of drugs with sedative properties (Sloane et al. 
2008). Among those participants, men used drugs with sedative properties more 
frequently than women. The most frequently used Group 1 drugs was lorazepam, Group 2 
drugs were olanzapine and risperidone, and Group 3 drugs were donepezil and atenolol. 
Participants without dementia had a higher sedative load than participants with dementia. 
The generalizability of these findings is unknown.  
The Drug Burden Index has been used to describe sedative and anticholinergic drug use 
among various patient populations and in a range of countries (Table 2). The prevalence of 
sedative drug use in studies utilizing the DBI is not fully comparable to other studies 
because drugs with both anticholinergic and sedative properties are classified as 
anticholinergic (for example, antipsychotics and tricyclic antidepressants). Among 
community-dwelling participants, the use of sedative drugs has varied from 13% to 16% 
(Hilmer et al. 2007, Cao et al. 2008, Gnjidic et al. 2009). A recent study of DBI among frail 
older community-dwelling participants found that 46% frail participants were exposed to 
DBI drugs compared to 20% of robust participants (Gnjidic et al. 2012). Among 
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institutional based samples, the prevalence of sedative drug use ranged from 26% to 42% 
(Wilson et al. 2010, Gnjidic et al. 2011, Lowry et al. 2011).  
Among community-dwelling Finns participating in the GeMS Study, 37% were exposed 
to DBI contributing drugs. DBI exposure was higher than among community-dwelling 
older people in Australia (Gnjidic et al. 2009) and the United States (US) (Hilmer et al. 
2007). The most frequently used drugs contributing to DBI were zopiclone, temazepam, 
and tamsulosin.  
Studies utilizing the CNS drug model have all been conducted among the community-
dwelling participants of the Health, Aging and Body Composition Study (Table 2). In this 
study, 14% were users of CNS active drugs. Of drugs included in the CNS drug model, the 
most commonly used drugs were benzodiazepines (6%) and antidepressants (6%). 
Interestingly, Hilmer et al. conducted a study with DBI in the same study sample, and 
reported that 14% were users of sedative drugs according to DBI definition (Hilmer et al. 
2007). The Health ABC Study was a longitudinal study, and prevalence of CNS drug use 
increased from 14% to 18% during a 5-year follow-up (Hanlon et al. 2009). 
2.3.3 Prevalence of use of primary sedatives and drugs with sedation as a prominent 
side effect 
In a study by Linjakumpu et al., 88% of community-dwelling Finns aged ≥64 years used 
any drugs (Linjakumpu et al. 2003). Of them, 29% used Group 1 sedative drugs and 19% 
used Group 2 sedative drugs. Use of specific drug groups is outlined in Table 3. Hypnotics 
(15%) and anxiolytics (10%) were the most prevalent drugs whereas antidepressant use 
(6%) and antipsychotic use (3%) was less common (Linjakumpu et al. 2002).  
 
Table 3. Prevalence of use of primary sedatives and drugs with sedation as a prominent side 
effect among community-dwelling older people and residents of long-term care facilities 
 
Drug group Linjakumpu et al. 2002 
community-dwellinga 
Users % 
Taipale et al. 2009 
long-term care facilities 
Users % 
Primary sedatives   
Anxiolytics 10 36 
Hypnotics 15 29 
Conventional antipsychotics  17 
Tricyclic antidepressants  3 
Drugs with sedation as a prominent side effect 
Atypical antipsychotics  30 
SSRIs  28 
Other 2nd gen. antidepressants  10 
Antiepileptics 1 21 
Opioids 4 19 
a Prevalence reported among users of drugs (88% of the study sample) 
SSRIs = selective serotonin reuptake inhibitors 
 
 
Among residents with dementia in residential aged care facilities in Northern Ireland, 
drug use was compared between the six facilities included in the study (Parsons et al. 
2011). The prevalence of regular antidepressant use ranged from 33% to 68% and SSRIs 
were the most frequently used antidepressants. Regular use of hypnotics and anxiolytics 
ranged from 5% to 21% across the facilities. Residents of one facility were not using 
hypnotics whereas anxiolytic use was not found in two of the six facilities compared. The 
prevalence of antipsychotic use ranged from 10% to 41% across facilities. Atypical 
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antipsychotics were the most commonly used but there was one facility in which only 
conventional antipsychotics were prescribed. 
In a study conducted among residents of long-term care facilities in Helsinki, only 15% 
of all 1004 participants were nonusers of drugs with sedative properties (Taipale et al. 
2009). The residents had a high level of comorbidity, with 77% diagnosed a dementia, 26% 
depression and 46% had suffered a stroke. Use of Group 1 and 2 sedative drugs was about 
two to five times more frequent among residents of long-term care facilities than among 
community-dwelling Finns in studies conducted by Linjakumpu et al. (Table 3). The 
difference may be even larger because Linjakumpu et al. reported that the prevalence 
among users of drugs (88% of the sample), and included also when-required drug use 
whereas in long-term care facilities only regular drug use was considered. However, 
anxiolytics and hypnotics were the most frequently used drug groups in both settings.  
Bell et al. reported sedative drug use in the same long-term care facilities comparing 
drug use among those with and without dementia (Bell et al. 2010). Residents with 
dementia were more frequent users of antipsychotics but less frequent users of 
antidepressants and benzodiazepines than residents without dementia. The most 
frequently used Group 1 drugs among residents with dementia were temazepam (16%), 
oxazepam (13%) and lorazepam (12%).  
2.4 PHYSICAL FUNCTIONING IN OLD AGE 
2.4.1 Changes in physical function related to aging 
Aging is typically associated with a gradual decrease in muscle mass and muscle strength. 
Significant decreases in muscle mass are seen between ages of 60 and 80 years (Kyle et al. 
2001). This slow decline may not be noted by older persons themselves. An aging-related 
decline in physical activity contributes to the loss of muscle mass and the accumulation of 
adipose tissue (Evans et al. 1993). Among older people, overall loss of weight may be 
hazardous because loss of fat body mass has been associated with bone loss (Bleicher et al. 
2011). 
Muscle strength is required in daily motor tasks such as walking, and in control of 
postural balance during standing, walking and recovering from balance disturbations 
(Rantanen 2003b). The minimum amount of muscle strength for motor tasks such as 
walking varies, and one important factor mediating the variance is presence or absence of 
balance impairment. Muscle strength is needed to compensate balance impairment caused 
by other factors. However, muscle strength is a major factor in balance, walking and the 
occurrence of falls (Wolfson et al. 1995).  
A certain amount of muscle strength is needed to perform necessary Activities of Daily 
Living (ADLs) (Rantanen 2003b). When strength is adequate, there is a certain amount of 
reserve capacity which is a safety margin that helps to prevent disability from developing. 
Without reserve capacity, physical inactivity related to an illness or other factors causing 
immobilization may decrease muscle strength so that ADLs cannot be performed 
anymore. Impaired muscle strength has been associated with important outcomes 
including impaired performance in ADLs, Instrumental Activities of Daily Living (IADLs), 
and with an increased risk of death (Newman et al. 2006, Cooper et al. 2010, Hairi et al. 
2010). Lower extremity muscle weakness has also been associated with an increased risk of 
falling (Moreland et al. 2004). Thus, poor muscle strength possesses a threat to 
independent living and functioning among older people (Gill et al. 1995, Penninx et a. 
2000).  
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Besides muscle strength, aging also affects other factors involved in control of postural 
balance. Postural balance is interplay between sensory information from somatosensory, 
vestibular and visual systems, processing this information in the CNS and then producing 
different movement strategies depending on the goals and environmental challenges 
(Horak 2006). With aging, declines occur in all these systems which challenge the 
maintenance of postural balance and independent mobility. Furthermore, mobility and 
postural reactions require cognitive processing and abilities to rapidly reallocate attention 
which may also be challenged by the aging process and comorbid diseases (Maki et al. 
2001, Woollacott et al. 2002).  
2.4.2 Muscle strength measures 
The grip strength test is one of the most common muscle strength tests among older 
people. Hand grip strength is straightforward to measure with dynamometer, and results 
of it has been shown to correlate well with strength of other muscle groups and can be 
used as an indicator of overall strength (Rantanen et al. 1994). Impaired hand grip strength 
has been associated with various adverse events among older people including an 
increased risk of falling (Pijnappels et al. 2008), disability in IADLs (Giampaoli et al. 1999, 
Hairi et al. 2010), and mortality (Rantanen et al. 2003a, Newman et al. 2006). In the 
Hertfordshire Cohort Study conducted in the United Kingdom it was demonstrated that a 
2.0 kg decline in grip strength among men and women aged 59‒73 years was equivalent to 
five years of chronological ageing (Ashfield et al. 2010). 
Knee extension strength can be measured in sitting position using a dynamometer 
chair. This test measures maximal strength produced by lower extremities against 
unmoving target. Poor results in knee extension strength test has been associated with risk 
of mobility decline (Visser et al. 2005, Buchman et al. 2007), falling (Pijnappels et al. 2008), 
and mortality (Newman et al. 2006). Muscle strength and mobility are correlated with each 
other because poor muscle strength in lower extremities has been associated with slower 
walking speed (Tiedemann et al. 2005).  
The chair stands test assesses the basic ability to perform sit-to-stand transfers 
(Guralnik et al. 1994). It measures the strength of lower extremities but also aspects of 
balance that are needed in this basic activity of daily living. Poor performance in the chair 
stands test has been associated with clinically important outcomes. Those who need ≥17.1 
seconds to complete five chair stands have been shown to be at higher risk of developing 
persistent severe lower extremity limitation, and at higher risk of death (Cesari et al. 2009).  
A recent systematic review and meta-analysis of objective measures of physical 
capability concluded that weaker grip strength is associated with an increased risk of 
fractures and cognitive decline in most studies conducted among older people (Cooper et 
al. 2010). The same review reported similar findings in relation to chair stands, although 
the number of studies examining this parameter was relatively small. The review 
concluded that objective performance measures are predictors of all-cause mortality, and 
these measures can be useful as markers of current and future health status.  
2.4.3 Mobility and balance measures 
Mobility among older persons can be measured with various performance based tests. 
One of the most common tests is measurement of maximal walking speed (Guralnik et al. 
2000, Cesari et al. 2005). The method is quick and easy to use, inexpensive and highly 
reliable. Walking speed measured over a short distance, such as 10 meters, assesses 
neuromuscular function of the lower extremities (Aniansson et al. 1980). In the walking 
speed test, a substantial and meaningful change is 0.10 m/s (Gill et al. 2010). This level of 
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change has been related to adverse outcomes. Slow walking speed among older people is 
associated with an increased rate of hospitalization, an increased risk of falls and fractures, 
need for a caregiver, and mortality (Montero-Odasso et al. 2005, Morris et al. 2007). 
Walking is also a component of another test called the Timed Up & Go Test (TUG) 
where a participant is asked to stand up from a chair, walk 3 meters, turn around, walk 
back and sit down (Podsiadlo et al. 1991). The TUG is more of a functional task involving 
activities required in daily living. Poor performance in TUG has been associated with an 
increased risk of falling (Shumway-Cook et al. 2000, Morris et al. 2007). In the TUG, those 
who need longer than 14.0 seconds to complete the test have been shown to be at higher 
risk of falling (Shumway-Cook et al. 2000). 
Mobility may also be assessed using participant self-reports to assess participant’s 
perception of his or her own mobility status. Typically, participants are asked about their 
abilities, difficulties or need for help in specific tasks, such as ability to walk 400 meters 
(Sayers et al. 2004). Self-reported difficulty in walking has been found to be a reliable and 
valid measure of mobility limitation (Fried et al. 2001). Self-reported measures 
complement performance based measures because they reflect actual performance in daily 
living whereas performance measures assess performance in ideal and controlled 
conditions (Latham et al. 2008).  
Berg Balance Scale (BBS) measures various abilities related to balance, including 
standing and reaching tasks (Berg et al. 1992). Tasks begin with easier and progress to 
tasks that require higher balancing functions. Berg Balance Scale has found to be reliable 
measure of balance among older people (Berg et al. 1992, Steffen et al. 2002). Low BBS 
scores have been shown to predict a risk of falling (Lajoie et al. 2002). 
2.5 APPROACHES TO OPTIMIZE DRUG USE AMONG OLDER PEOPLE 
Studies regarding adverse events associated with psychotropic and sedative drug use 
among older people have prompted initiatives to optimize drug use. These approaches 
include regulatory warnings of ADEs (Dorsey et al. 2010), education of health care 
professionals (Pimlott et al. 2003), education and counseling of patients regarding 
withdrawal or reduction of benzodiazepine use (Salonoja et al. 2010, Smith and Tett 2010), 
medication reviews by pharmacists (Zermansky et al. 2006, Holland et al. 2008), 
medication assessments by physicians (Pit et al. 2007), multidisciplinary team 
interventions including Comprehensive Geriatric Assessment (CGA) (Frankfort et al. 2006, 
Tulner et al. 2010), and withdrawal programs (Voshaar et al. 2003, Parr et al. 2009). In this 
literature review, CGA, medication reviews and withdrawal strategies from use of 
benzodiazepines are briefly reviewed in terms of optimizing sedative drug use.  
2.5.1 Comprehensive Geriatric Assessment (CGA)  
Comprehensive Geriatric Assessment is a diagnostic process to determine an older 
person’s medical, psychosocial, and functional capacity related problems (Rubenstein 
1984). The process is multidimensional and utilized with an objective of developing a plan 
for treatment and rehabilitation, and to promote older person’s health and independence. 
The CGA typically involves a geriatrician, nurse, physiotherapist and depending on the 
problems other healthcare providers such as occupational therapist, social worker, 
psychologist and other consultants such as physicians specialized in orthopedics or 
cardiology. The process is individually tailored according to needs and problems of the 
participant.   
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Geriatric clinical examination including laboratory tests and interview in CGA is 
targeted to identify new diseases, to assess cognition and status of chronic diseases and 
other medical problems (Rubenstein 1984). Functional capacity is one important 
dimension which focuses on how person copes with ADLs and IADLs, and mobility tasks. 
Psychosocial health includes examination of mood and quality of life. Finally, socio-
environmental aspect includes social networks and support, environmental safety and 
need of services.  
The effectiveness of CGA has been studied mainly when a person is discharged from 
hospital to geriatric evaluation and management units (Van Craen et al. 2010). A meta-
analysis by van Craen et al. concluded that CGA significantly affected functional decline 
and institutionalization after one year. However, mortality, hospital readmission and 
length of hospital stay were not affected by this intervention.  
Medication assessment is a central part of the CGA because polypharmacy and ADEs 
are frequent among older people (Jyrkkä et al. 2006, Hilmer et al. 2009b). The CGA and 
medication assessment conducted at a diagnostic geriatric day clinic have resulted in 
relevant changes in medications in one study (Frankfort et al. 2006). These changes were 
often discontinuations of drugs when indication of drug was no longer relevant. Adverse 
events were detected and better pharmacotherapeutic options were proposed. However, 
the number of drugs was reduced in only a minority of patients because of prescribing 
new drugs for diseases diagnosed in the CGA. This is consistent with another study 
assessing effects of CGA on drug use (Tulner et al. 2010). The CGA increased mean 
number of drugs used and the prevalence of polypharmacy. The increase was caused by 
new indications treated with drug therapy and a decrease in the under-treatment of 
existing diseases. The effect of medication assessment cannot be only judged by the 
number of drugs but quality of drug use and optimal care of diagnosed diseases. 
Medication assessment outside of the CGA process has been reported to be effective in 
reducing regular use of benzodiazepines among older people with a recent history of falls 
(Salonoja et al. 2010). A Finnish randomized controlled trial included medication 
assessment, lecture on adverse effects of psychotropic drugs, and written instructions on 
how to reduce the use of psychotropic drugs. The intervention reduced the number of 
regular users of benzodiazepines by 35% after a 12-month follow-up. No changes were 
observed in irregular benzodiazepine use, or use of antipsychotics and antidepressants. 
However, an Australian study reported that medication assessment by a general 
practitioner did not decrease benzodiazepine use among community-dwelling older 
people (Pit et al. 2007).  
2.5.2 Medication reviews related to sedative drug use and ADEs 
Medication reviews are one important method to reduce and re-evaluate use of 
psychotropic and sedative drugs among older people (Nishtala et al. 2008). Meta-analysis 
by Nishtala et al. concluded that a combination of medication review and/or educational 
interventions for physicians and nursing staff are effective in reducing hypnotic use in 
long-term care facilities. Pharmacist involvement in medication review process has been 
successful in reducing ADEs including falls among older people (Zermansky et al. 2006). 
A systematic review and meta-analysis by Holland et al. concluded that pharmacist-led 
medication reviews aimed at optimizing drug regimens were not effective in reducing 
hospital admissions, or mortality (Holland et al. 2008). Medication reviews may have 
clearer impact on ADEs and other outcomes if they are targeted to a specific patient group 
(those with an increased risk of falls, or long-term users of benzodiazepines), or when 
pharmacists are a part of multidisciplinary team (Schmader et al. 2004). 
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Pharmacist-led medication reviews have reduced patient’s DBI scores in both 
community and residential-aged care settings (Nishtala et al. 2009, Casteliano et al. 2010). 
In a study by Casteliano et al., DBI scores before and after Home Medicines Review by 
pharmacist were compared retrospectively for 372 older persons who were referred to the 
service (Casteliano et al. 2010). Drugs contributing to DBI were identified in 52% of the 
participants before the medication review which indicates high use of the DBI drugs. 
Medication reviews significantly reduced the total sum of DBI scores for all participants 
(p<0.001), and majority of pharmacists’ recommendations were to withdraw or reduce the 
usage of benzodiazepines.  
2.5.3 Withdrawal from benzodiazepine use 
Clinical studies of drug withdrawal suggest that withdrawal is rarely associated with 
ADEs (Iyer et al. 2008). Withdrawal is usually associated with no deteriation in clinical 
status, and psychotropic drug withdrawal may improve cognition and reduce the risk of 
falls.  
Long-term use of benzodiazepines has been found to be associated with a risk of 
cognitive decline among older people (Paterniti et al. 2002). Gradual decrease in dose with 
weekly visits to general practitioner has been successful in discontinuation of long-term 
benzodiazepine use (Voshaar et al. 2003). One-time counseling and medication assessment 
by geriatrician in combination with education of patients with history falls resulted 
decrease in regular benzodiazepine use (Salonoja et al. 2010). Withdrawal from addictive 
drugs such as benzodiazepines is shown to be effective when withdrawal is done by 
gradual decrease in dose (Parr et al. 2009). Withdrawal from drugs should be done in 
collaboration with the patient. Clinicians should emphasize the benefits of withdrawal 
because older users are often psychologically dependent on benzodiazepines, deny or 
minimize adverse effects, express resistance to discontinuation and may have tried to 
discontinue without results (Iliffe et al. 2004, Cook et al. 2007). However, meta-analysis 
conducted by Barker et al. demonstrated that long-term benzodiazepine users show 
recovery of cognitive function after withdrawal (Barker et al. 2004).  
2.6 ADVERSE EVENTS ASSOCIATED WITH THE USE OF DRUGS WITH 
SEDATIVE PROPERTIES 
2.6.1 Adverse events associated with cumulative exposure to sedative drugs 
The Sedative Load Model, DBI and CNS drug model have been used to study the 
association between cumulative exposure to sedative drugs and clinically important ADEs 
in older people (Table 4). Associations between DBI and ADEs have been investigated in 
10 studies, and seven of these have been focused on declines in physical function. Of these 
seven studies, five have been conducted among community-dwelling older people, one 
among persons in residential aged care facilities, and one among persons living in self-care 
retirement villages in Australia. Furthermore, one study was conducted among acutely ill 
hospitalized older people, and was focused on ADLs. The association between DBI and 
ADEs has been studied in six cross-sectional and four longitudinal studies. Three studies 
have reported association between CNS drug use and ADEs, and all three studies utilized 
longitudinal study design (Health ABC Study). One of these three studies investigated 
association between CNS drug use and physical function. The association between 
sedative load and ADEs has only been studied in one study.  
18 
 
 
DBI drugs have been shown to impair physical function in grip strength, chair stands, 
walking speed, self-reported physical function measures, TUG and Berg Balance Scale 
among community-dwelling older people in the United States, Australia and Finland 
(Table 4). However, studies among residents of residential aged care facilities and self-care 
retirement villages have demonstrated more modest associations (Wilson et al. 2010, 
Gnjidic et al. 2011b). A study by Boudreau et al. found an association between CNS drug 
use and risk of incident self-reported mobility limitation (Boudreau et al. 2009). Cognitive 
function has been studied in one DBI study and in one CNS Drug Model study (Hilmer et 
al. 2007, Wrigth et al. 2009), and both found that cumulative exposure to sedative drugs 
was associated with poor cognitive function.  
Three studies have investigated the association between cumulative exposure to 
sedative drugs and risk of death (Table 4). However, there remains a lack of research on 
mortality associated with cumulative exposure to sedative drugs. There is also a lack of 
studies concerning cumulative exposure to sedative drugs and the risk of falls. One study 
found that CNS drug use was associated with an increased risk of falls among 
community-dwelling older people (Hanlon et al. 2009). A recent study found an 
association between DBI and an increased risk of falls among older people in residential 
aged care facilities (Wilson et al. 2011). The risk of falls remains an important area for 
further research because benzodiazepine use has been associated with falls and hip 
fractures (Cumming & LeCouteur 2003, Hartikainen et al. 2007). Falls may result in serious 
injuries, including fractures, visits to emergency department, and also admissions to 
nursing homes (Dunn et al. 1993, Kannus et al. 2005). 
2.6.2 Impairment of physical function associated with sedative drugs 
Association between sedative drug use and physical function has been studied among 
older people (Table 5). Benzodiazepines are the most widely studied sedative drug group 
in relation to physical function. Of 12 studies included in Table 5, six studied solely 
benzodiazepines. Antidepressant use was investigated in four studies, antipsychotic use in 
two studies and opioid use only in one study. Two studies investigated associations 
between use of ≥1 psychotropic drugs and performance in balance and muscle strength 
tests (Lord et al. 1992, Lord et al. 1995).  
Benzodiazepines have been consistently associated with declines in ADLs/ IADLs, and 
self-reported declines in mobility (Table 5). Of performance-based tests, one study of 
muscle strength did not report an association with benzodiazepine use. SPPB/ EPESE 
scales and mobility (walking speed) have been investigated in two studies each, and 
resulted in opposite conclusions. The majority of studies (two out of three) on 
benzodiazepine use and poor balance have found an association. However, the lack of 
associations may be related to small sample sizes in studies with performance-based 
physical function measures (number of participants varied from 12 to 885). Furthermore, 
many of these studies also included users of psychotropic drugs other than 
benzodiazepines. However, benzodiazepines have also been shown to impair physical 
function among younger adults, including balance measured as body sway (McClelland 
1989), and impairment of psychomotor skills and car driving ability (Verster et al. 2007). In 
conclusion, there is evidence of an association between benzodiazepine use and physical 
function decline.  
Antidepressant use has been associated with a decline in ADLs/ IADLs, muscle strength 
and mobility (Table 5). However, there are also two studies which could not found 
associations, and overall number of studies regarding antidepressant use is small. In a 
study by Draganich et al. found an association between declines in mobility and use of 
19 
 
 
amitriptyline but not with use of desipramine or paroxetine (Draganich et al. 2001). Thus, 
there may be differences in impacts on physical function within drug classes.  
The number of studies about sedative drugs other than benzodiazepines and 
antidepressants is too small to make any conclusions (Table 5). A review of antiepileptic 
use and balance disturbances among older people concluded that some antiepileptics 
including primidone, phenobarbital, phenytoin and carbamazepine appear to produce a 
greater impairment of balance compared to newer antiepileptic drugs, but there is a 
considerable lack of research on the topic (Fife and Sirven 2005). Altogether, the number of 
studies regarding sedative drugs and decline in physical function is remarkably small 
when considering the variety of sedative drugs, prevalence of use among older people, 
and concern about possible decline in physical function related to the use of sedative 
drugs. Research utilizing cumulative exposure methods of sedative drug use has started to 
fill this gap in recent years.  
Impairment of physical function related to sedative drug use may also be consequence 
of physical inactivity caused by these drugs. This may result in disuse atrophy (Clark 
2009). Higher level of physical activity has been associated with a slower rate of mobility 
decline (Buchman et al. 2007). In addition, physical inactivity may result in decreased 
muscle strength (Rantanen et al. 1999, Goodpaster et al. 2008). Sedation caused by drugs 
may cause or worsen physical inactivity which may result in decline in muscle strength 
and thus, poorer physical function. 
2.6.3 Mortality associated with the use of sedative drugs 
There are three studies of mortality and sedative drug use utilizing one of the four 
methods to assess cumulative exposure to drugs with sedative properties (Taipale et al. 
2009, Lowry et al. 2011, Wilson et al. 2012, Table 4). The study by Taipale et al. was 
conducted among 1004 residents of long-term care facilities in Finland, whereas Lowry et 
al. studied 362 older hospitalized, acutely ill patients in the UK. Wilson et al. studied 
mortality among 602 older people living in residential aged care facilities in Australia. All 
three studies have concluded that there was no association between sedative drug use and 
mortality.  
Drug classes contributing to sedative load have been associated with an increased risk 
of death among older people (Table 6). Antipsychotics are the most frequently studied 
drug group in relation to mortality, with at least 18 original studies conducted among 
older people or persons with dementia. Of these 18 studies, 15 have reported an increased 
risk of death associated with antipsychotic use.  
The first meta-analysis that led to warnings of mortality risk associated with atypical 
antipsychotic use was published in 2005 by Schneider et al. (Schneider et al. 2005). In the 
analysis of 3353 participants, older persons randomized to atypical antipsychotics were at 
higher risk of death compared to those prescribed placebo (meta-analysis odds ratio [OR] 
1.54, CI 1.06‒2.23). Subsequent studies have also demonstrated an increased mortality risk 
with conventional antipsychotics (Table 6). Wang et al. reported that conventional 
antipsychotics were associated with a significantly higher risk of death compared to 
atypical antipsychotics (Wang et al. 2005), and this have been also found in other studies 
(Schneeweiss et al. 2007, Gill et al. 2007, Setoguchi et al. 2008, Liperoti et al. 2009, Musicco 
et al. 2011). Two studies have reported a similar risk of death for conventional and atypical 
antipsychotic use (Trifiro et al. 2007, Kales et al. 2007). The studies also indicate that risk of 
death may be highest in the start of the treatment (Wang et al. 2005, Schneeweiss et al. 
2007, Rossom et al. 2010). 
20 
 
 
A review by Mittal et al. concluded that current data indicates that the risk of death 
with atypical and conventional antipsychotics is greater than when compared to placebo 
group or nonusers of antipsychotics (Mittal et al. 2010). According to 14 reviewed studies, 
the risk was estimated to be 1.2 to 1.6 times higher in the antipsychotic treated group. The 
risk was found to similar for both atypical and conventional antipsychotics, and no one 
drug has been found to be safer than other. The mortality risk was estimated to be 
elevated in the first 30 days of treatment and possibly until 2 years. 
The most recent studies have concentrated on specific antipsychotics, and associated 
risk of death (Rossom et al. 2010, Kales et al. 2012, Table 6). In both studies, haloperidol 
was associated with the highest risk of death during the first 30-180 days of treatment, HR 
1.5-3.2. Rossom et al. found an increased risk of death associated with also olanzapine and 
risperidone use but not for quetiapine use, and Kales et al. reported similar results. 
Further studies with large study samples are needed to assess the risk of death associated 
with specific antipsychotic drugs. 
Studies concerning other drug classes than antipsychotics have presented conflicting 
results (Table 7). In some studies of antipsychotics and mortality among participants with 
dementia, antipsychotic use has been associated with higher mortality rate compared to 
users of other psychiatric medications including antidepressants (Kales et al. 2007). In a 
recent study of specific antipsychotic drugs among incident users with dementia, valproic 
acid use was associated with a similar risk as olanzapine and risperidone (Kales et al. 
2012). Thus, results of other sedative drugs in comparison to antipsychotics are 
inconsistent.  
Of five reviewed studies regarding antidepressant use and mortality, two have not 
found any association (Barnett et al. 2006, McCusker et al. 2006), two have found an 
increased risk of death (Ryan et al. 2008, Coupland et al. 2011) and one a lower risk of 
death (Ried et al. 2011) (Table 7). This may be partly related to different patient 
characteristics in different studies. Studies have been conducted among participants with 
pneumonia (Barnett et al. 2006), among participants with diagnosed depression (Coupland 
et al. 2011), and among veterans who have had a stroke (Ried et al. 2011). Antidepressants 
may be used in various indications, and underlying diseases may affect the risk of death.  
Studies regarding benzodiazepines and mortality among older people have been 
inconclusive in results, and heterogeneous when considering the definition of drugs 
(Table 7). Some studies included hypnotics, some included anxiolytics and hypnotics, 
benzodiazepines or “sleeping pills”. Some studies used administrative dispensing data 
and other used survey based data. Four studies have not found an association (Rumble et 
al. 1992, Merlo et al. 2000, Vinkers et al. 2003, Gisev et al. 2011), whereas three studies have 
reported at least partly positive results (Merlo et al. 1996, Kripke et al. 1998, Lopez et al. 
1999). In a study by Merlo et al., combined use of anxiolytic-hypnotics and analgesics was 
associated with all-cause mortality and with ischemic heart disease mortality (Merlo et al. 
1996). Kripke et al. found an association between hypnotic use and an increased risk of 
death among older men but among women (Kripke et al. 1998). Lopez et al. reported an 
increased mortality risk among sedative-hypnotic users compared to nonuse in small 
sample (n=179) of participants with dementia (Lopez et al. 1999). However, hypnotic use 
has been associated with an increased risk of death among middle-aged persons (Kripke et 
al. 2012) and thus, further research is needed to establish this association among older 
persons. 
Opioids were studied in one study among older people diagnosed with osteoarthritis or 
rheumatoid arthritis (Solomon et al. 2010a, Solomon et al. 2010b). Compared to use of non-
steroidal anti-inflammatory drugs (NSAIDs), opioids were associated with an increased 
risk of death (Solomon et al. 2010a). Among opioid users, oxycodone and codeine were 
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associated with an increased risk of death compared to hydrocodone use after 30 days of 
exposure (Solomon et al. 2010b). These two studies by Solomon et al. questioned the safety 
of opioid use among older people. However, opioids may have been selectively prescribed 
to older people at higher risk of death. 
There are several potential mechanisms behind sedative drugs and an increased risk of 
death. Antipsychotics have been associated with prolongation of QT interval and sudden 
cardiac deaths (Straus et al. 2004). Other possible causes of death associated with 
antipsychotics are cerebrovascular adverse events which may be related to orthostatic 
hypotension caused by antagonism of alpha-adrenergic receptors (Mittal et al. 2011). This 
may result in a decrease in cerebral perfusion. The risk of cerebrovascular adverse events 
has been shown to be similar with conventional and atypical antipsychotics, and 
associated with therapy lasting for more than 30 days (Mehta et al. 2010). Sedation and 
extrapyramidal symptoms that may contribute to swallowing problems and 
corresponding risk of pneumonia, have also been suggested as possible mechanisms of an 
increased risk of death associated with antipsychotic use among older people (Liperoti et 
al. 2009, Mittal et al. 2010).  
Causes of deaths that have been related to hypnotic use include suicide, cancer, and 
confounding by indications insomnia and depression (Kripke 2009). One potential cause of 
death related to psychotropic drug use is an increased risk of falls and fractures which 
have been associated with all discussed drug classes (Cumming and Le Couteur 2003, 
Hartikainen et al. 2007). However, there is a lack of studies concerning mechanisms and 
causes of death related to sedative drug use. 
In conclusion, studies regarding antipsychotics and an increased risk of death are 
numerous, conducted among patients with and without dementia, and the risk has been 
demonstrated with both conventional and atypical antipsychotics. The risk is elevated at 
the start of the treatment but is associated also with long-term use. Evidence related to 
other drugs with sedative properties does not clearly indicate whether or not use of these 
drugs among older people is associated with an increased risk of death. Further studies 
are needed to assess the possible association between sedative drug use and mortality. 
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ti
fy
 
cu
m
u
la
ti
ve
 
ef
fe
ct
 o
f 
se
d
at
iv
e 
d
ru
g
s 
S
tu
d
ie
d
 o
u
tc
om
es
 
A
ss
oc
ia
ti
on
 o
f 
se
d
at
iv
e 
d
ru
g
 
u
se
 w
it
h
 t
h
e 
ou
tc
om
es
 (
vs
. 
n
o 
u
se
) 
H
ilm
er
 e
t 
al
. 
20
07
  
U
S
, 
H
ea
lth
 
A
B
C
 s
tu
dy
 
30
75
 
A
ge
 r
an
ge
 7
0‒
79
 
y,
 m
ea
n 
ag
e 
74
 
ye
ar
s,
 5
2%
 
w
om
en
 
C
 
C
S
 
D
B
I 
S
PP
B
 (
m
od
ifi
ed
),
 D
S
S
T 
sc
or
es
 
Po
or
er
 S
PP
B
 s
co
re
s 
(p
<
0.
00
1)
 a
nd
 
po
or
er
 D
S
S
T 
sc
or
es
 (
p=
0.
01
) 
am
on
g 
th
os
e 
ex
po
se
d 
to
 D
B
I 
dr
ug
s 
C
ao
 e
t 
al
. 
20
08
 
U
S
, 
W
om
en
s’
 
H
ea
lth
 a
nd
 
A
ge
in
g 
S
tu
dy
 
93
2 
≥
65
 y
ea
rs
, 
m
ed
ia
n 
ag
e 
78
 
ye
ar
s,
 
10
0%
 w
om
en
 
C
 
C
S
 
D
B
I 
M
M
S
E,
 A
D
L,
 w
al
ki
ng
 s
pe
ed
, 
m
ob
ili
ty
 (
se
lf -
re
po
rt
ed
),
 
ba
la
nc
e 
(f
ul
l t
an
de
m
 s
ta
nd
),
 
ch
ai
r 
st
an
ds
, 
up
pe
r 
ex
tr
em
ity
 f
un
ct
io
n 
(s
el
f -
re
po
rt
ed
),
 g
ri
p 
st
re
ng
th
 
D
B
I:
  
im
pa
ir
ed
 g
ri
p 
st
re
ng
th
 O
R
 3
.3
 
(1
.5
‒7
.3
),
  
m
ob
ili
ty
 d
iff
ic
ul
ty
 O
R
 
2.
4 
(1
.1
‒5
.3
),
  
±
 o
th
er
 o
ut
co
m
es
, 
D
B
I A
N
TI
C
H
O
L:
  
po
or
er
 p
er
fo
rm
an
ce
 in
 a
ll 
ou
tc
om
es
  
G
nj
id
ic
 e
t 
al
. 
20
09
  
A
us
tr
al
ia
, 
C
on
co
rd
 
H
ea
lth
 a
nd
 
A
ge
in
g 
in
 M
en
 
Pr
oj
ec
t  
17
05
 
 
≥
70
 y
, 
 
m
ea
n 
ag
e 
77
, 
10
0%
 m
en
 
C
 
C
S
 
D
B
I 
IA
D
L,
 b
al
an
ce
 (
sw
ay
),
 
w
al
ki
ng
 s
pe
ed
, 
na
rr
ow
 w
al
k,
 
ch
ai
r 
st
an
ds
, 
g r
ip
 s
tr
en
gt
h 
D
B
I:
 p
oo
re
r 
pe
rf
or
m
an
ce
 in
 I
A
D
L,
 
w
al
ki
ng
 s
pe
ed
, 
na
rr
ow
 w
al
k,
 
ba
la
nc
e 
an
d 
gr
ip
 s
tr
en
gt
h 
(p
<
0.
05
),
  
D
B
I S
ED
: 
po
or
er
 p
er
fo
rm
an
ce
 in
 
IA
D
L,
 w
al
ki
ng
 s
pe
ed
, 
na
rr
ow
 w
al
k,
 
ba
la
nc
e 
an
d 
gr
ip
 s
tr
en
gt
h 
(p
<
0.
05
) 
H
ilm
er
 e
t 
al
. 
20
09
 
U
S
, 
H
ea
lth
 
A
B
C
 S
tu
dy
 
21
72
 
70

79
 y
, 
 
52
%
 w
om
en
  
C
 
L 
D
B
I 
Fu
nc
tio
na
l p
er
fo
rm
an
ce
 
as
se
ss
ed
 w
ith
 S
PP
B
, 
us
ua
l 
w
al
ki
ng
 s
pe
ed
 a
nd
 g
ri
p 
st
re
ng
th
 
D
B
I:
 lo
w
er
 S
PP
B
 s
co
re
s 
(p
=
0.
01
),
  
lo
w
er
 w
al
ki
ng
 s
pe
ed
 (
p=
0.
00
4)
 
an
d 
lo
w
er
 g
ri
p 
st
re
ng
th
 (
p=
0.
00
4)
  
af
te
r 
5 
ye
ar
s 
W
ils
on
 e
t 
al
. 
20
10
 
A
us
tr
al
ia
 
52
6 
M
ea
n 
ag
e 
86
, 
72
%
 w
om
en
 
I 
L 
D
B
I 
Ph
ys
ic
al
 f
un
ct
io
n 
as
se
ss
ed
 
w
ith
 g
ri
p 
st
re
ng
th
, 
re
ac
tio
n 
tim
e,
 w
al
ki
ng
 s
pe
ed
 a
nd
 
ba
la
nc
e 
In
 lo
ng
itu
di
na
l a
na
ly
si
s,
 D
B
I:
 
po
or
er
 b
al
an
ce
 (
p=
0.
02
).
 
In
 c
ro
ss
-s
ec
tio
na
l a
na
ly
si
s,
 D
B
I S
ED
: 
 
po
or
 b
al
an
ce
 O
R
 1
.5
7 
(1
.0
8‒
2.
27
) 
G
nj
id
ic
 e
t 
al
. 
20
11
 
A
us
tr
al
ia
 
11
5 
M
ea
n 
ag
e 
82
, 
73
%
 w
om
en
 
I 
C
S
 
D
B
I 
S
PP
B
 a
nd
 g
ri
p 
st
re
ng
th
 
D
B
I:
 d
ec
re
as
e 
in
 S
PP
B
 s
co
re
 
(p
=
0.
04
) 
 
±
 g
ri
p 
st
re
ng
th
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  T
ab
le
 4
. 
C
on
tin
ue
d 
 
 
 
 
 
 
 
G
nj
id
ic
 e
t 
al
. 
20
11
 
Fi
nl
an
d,
 G
eM
S
 
S
tu
dy
 
70
0 
M
ea
n 
ag
e 
82
 (
al
l 
≥7
5)
, 
69
%
 
w
om
en
 
C
 
C
S
 
D
B
I 
Ph
ys
ic
al
 f
un
ct
io
n 
as
se
ss
ed
 
w
ith
 w
al
ki
ng
 s
pe
ed
, 
ch
ai
r 
st
an
ds
, 
gr
ip
 s
tr
en
gt
h,
 T
U
G
, 
IA
D
L 
an
d 
B
ar
th
el
 I
nd
ex
 
D
B
I:
 p
oo
re
r 
w
al
ki
ng
 s
pe
ed
, 
ch
ai
r 
st
an
ds
, 
TU
G
, 
IA
D
L 
an
d 
B
I 
(p
<
0.
00
1)
 
W
ils
on
 e
t 
al
. 
20
11
 
60
2 
M
ea
n 
ag
e 
86
, 
71
%
 w
om
en
 
I 
L 
D
B
I 
In
ci
de
nt
 r
at
e 
of
 f
al
ls
 d
ur
in
g 
fo
ll o
w
-u
p 
D
B
I:
 in
cr
ea
se
d 
ri
sk
 o
f 
fa
lls
, 
in
ci
de
nt
 r
at
e 
ra
tio
 f
or
 lo
w
 D
B
I 
1.
61
 
(1
.1
7 ‒
2.
23
) 
an
d 
fo
r 
hi
gh
 D
B
I 
1.
90
 
(1
.3
0‒
2.
78
) 
Lo
w
ry
 e
t 
al
. 
20
11
 
U
K
 
36
2 
M
ea
n 
ag
e 
84
, 
59
%
 w
om
en
 
I 
C
S
 
D
B
I 
B
ar
th
el
 I
nd
ex
, 
in
-h
os
pi
ta
l 
m
or
ta
lit
y 
H
ig
he
r 
D
B
I:
 lo
w
er
 B
I 
sc
or
es
, 
le
ng
th
 o
f 
st
ay
 in
 h
os
pi
ta
l H
R
 1
.2
3 
(1
.0
6‒
1.
42
),
  
±
 in
-h
os
pi
ta
l m
or
ta
lit
y 
H
R
 1
.1
7 
(0
.7
2‒
1.
90
) 
W
ils
on
 e
t 
al
. 
20
12
 
60
2 
M
ea
n 
ag
e 
86
, 
71
%
 w
om
en
 
I 
L 
D
B
I 
O
ne
-y
ea
r 
al
l-
ca
us
e 
m
or
ta
lit
y 
±
 m
or
ta
lit
y 
ri
sk
, 
 
D
B
I 
lo
w
 (
0‒
1)
 H
R
 1
.1
3 
(0
.8
2‒
1.
57
),
  
D
B
I 
hi
gh
 (
≥
1)
 H
R
 1
.1
9 
(0
.8
2‒
1.
74
) 
Ta
ip
al
e 
et
 a
l. 
20
09
 
Fi
nl
an
d 
10
04
 
M
ea
n 
ag
e 
81
, 
75
%
 w
om
en
 
I 
L 
S
ed
at
iv
e 
Lo
ad
 
M
od
el
 
A
ll-
ca
us
e 
m
or
ta
lit
y 
ov
er
 5
 
ye
ar
s  
±
 m
or
ta
lit
y 
ri
sk
 H
R
 1
.0
1 
(0
.9
1‒
1.
13
)  
W
ri
gh
t 
et
 a
l. 
20
09
  
U
S
, 
H
ea
lth
 
A
B
C
 S
tu
dy
 
27
37
 
≥
65
, 
53
%
 
w
om
en
 
C
 
L 
C
N
S
 D
ru
g 
M
od
el
 
C
og
ni
tiv
e 
de
cl
in
e 
du
ri
ng
 5
 
ye
ar
s,
 3
M
S
 s
co
re
 
C
og
ni
tiv
e 
de
cl
in
e 
H
R
 1
.3
7 
(1
.1
1‒
1.
70
)  
ov
er
 5
 y
ea
rs
 
B
ou
dr
ea
u 
et
 
al
. 
20
09
 
U
S
, 
H
ea
lth
 
A
B
C
 S
tu
dy
 
30
55
 
70
‒7
9,
  
52
%
 w
om
en
  
C
 
L 
C
N
S
 D
ru
g 
M
od
el
 
In
ci
de
nt
 m
ob
ili
ty
 li
m
ita
tio
n:
 
tw
o 
co
ns
ec
ut
iv
e 
se
lf -
re
po
rt
s 
of
 a
ny
 d
iff
ic
ul
ty
 w
al
ki
ng
 ¼
 
m
ile
 o
r 
cl
im
bi
ng
 1
0 
st
ep
s 
w
ith
ou
t 
re
st
in
g 
In
ci
de
nt
 m
ob
ili
ty
 li
m
ita
tio
n 
H
R
 
1.
28
 (
1.
12
‒1
.4
7)
 
H
an
lo
n 
et
 a
l. 
20
09
 
U
S
, 
H
ea
lth
 
A
B
C
 S
tu
dy
 
30
55
 
70
‒7
9 
52
%
 w
om
en
 
C
 
L 
C
N
S
 D
ru
g 
M
od
el
 
N
um
be
r 
of
 f
al
ls
 
R
is
k 
of
 f
al
ls
 O
R
 1
.9
5 
(1
.3
5‒
2.
81
) 
C
=
co
m
m
un
ity
-d
w
el
lin
g,
 I
=
in
st
itu
tio
na
l l
iv
in
g 
(i
n 
nu
rs
in
g 
ho
m
es
, 
lo
ng
-t
er
m
 c
ar
e 
fa
ci
lit
ie
s,
 r
es
id
en
tia
l a
ge
d 
ca
re
 f
ac
ili
tie
s)
, 
C
S
=
cr
os
s-
se
ct
io
na
l s
tu
dy
, 
L=
lo
ng
itu
di
na
l c
oh
or
t 
st
ud
y ,
 D
B
I 
=
 D
ru
g 
B
ur
de
n 
In
de
x,
 D
B
I S
ED
 =
 s
ed
at
iv
e 
co
m
po
ne
nt
 o
f 
D
ru
g 
B
ur
de
n 
In
de
x,
 D
B
I A
N
TI
C
H
O
L=
an
tic
ho
lin
er
gi
c 
co
m
po
ne
nt
 o
f 
D
ru
g 
B
ur
de
n 
In
de
x,
 D
S
S
T=
 D
ig
it 
S
ym
bo
l S
ub
st
itu
tio
n 
Te
st
, 
M
M
S
E=
 M
in
i-
M
en
ta
l S
ta
te
 E
xa
m
in
at
io
n,
 3
M
S
=
m
od
ifi
ed
 M
in
i-
M
en
ta
l S
ta
te
 E
xa
m
in
at
io
n,
 A
D
L 
=
 
A
ct
iv
iti
es
 o
f 
D
ai
ly
 L
iv
in
g,
 I
A
D
L=
 I
ns
tr
um
en
ta
l A
ct
iv
iti
es
 o
f 
D
ai
ly
 L
iv
in
g,
 B
I=
B
ar
th
el
 I
nd
ex
, 
TU
G
=
Ti
m
ed
 U
p&
G
o 
te
st
, 
C
N
S
 =
 c
en
tr
al
 n
er
vo
us
 s
ys
te
m
, 
H
R
=
 
ha
za
rd
s 
ra
tio
, 
O
R
 =
 o
dd
s 
ra
tio
, 
C
I 
=
 c
on
fid
en
ce
 in
te
rv
al
, 
H
ea
lth
 A
B
C
 =
 H
ea
lt
hy
, 
A
gi
ng
 a
nd
 B
od
y 
C
om
po
si
tio
n.
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  T
ab
le
 5
. 
A
ss
oc
ia
tio
ns
 b
et
w
ee
n 
se
da
ti
ve
 d
ru
g 
us
e 
an
d 
de
cl
in
e 
in
 p
hy
si
ca
l f
un
ct
io
n 
S
tu
d
y,
 c
ou
n
tr
y 
n
 
A
g
e 
P
at
te
rn
 
of
 u
se
 
S
tu
d
y 
d
es
ig
n
 
D
ru
g
 
A
D
Ls
/
 
IA
D
Ls
 
S
el
f-
re
p
or
te
d
 
m
ob
il
it
y 
M
ob
ili
ty
 
p
er
fo
rm
an
ce
 
S
P
P
B
, 
EP
ES
E
 
B
al
an
ce
 
M
u
sc
le
 
st
re
n
g
th
 
R
ie
d 
et
 a
l. 
19
98
 
U
S
 
41
92
 
 
≥
65
 
LT
 
L 
B
Z
D
 
+
 
 
 
 
 
 
G
ra
y 
et
 a
l. 
20
06
 
U
S
 
90
93
 
≥
65
 
LT
 
L 
B
Z
D
, 
an
y 
us
e 
B
Z
D
, 
sh
or
t -
ac
tin
g 
B
Z
D
, 
lo
ng
-a
ct
in
g 
 
B
Z
D
, 
hi
gh
er
 d
os
e 
+
 
+
 
±
 
+
 
+
 
+
 
+
 
+
 
 
 
 
 
G
ra
y 
et
 a
l. 
20
02
 
U
S
A
 
15
19
 
≥
65
 
LT
 
L 
B
Z
D
 a
nx
io
ly
tic
 u
se
 
B
Z
D
 h
yp
no
tic
 u
se
 
+
 
±
 
 
 
 
 
 
G
ra
y 
et
 a
l. 
20
03
 
U
S
 
88
5 
≥
70
 
LT
 
L 
B
Z
D
, 
an
y 
us
e 
B
Z
D
, 
hi
gh
er
 d
os
e  
B
Z
D
, 
lo
w
 d
os
e 
B
Z
D
, 
lo
ng
-t
er
m
 u
se
 
B
Z
D
, 
pa
st
 u
se
 
 
 
 
+
 
+
 
±
 
+
 
±
 
 
 
La
nd
i e
t 
al
. 
20
07
 
It
al
y 
36
4 
≥
80
 
LT
 
L 
B
Z
D
 
A
P 
+
 
+
 
 
±
 
±
 
+
 
±
 
 
±
 
±
 
Eb
ly
 e
t 
al
. 
19
97
 
C
an
ad
a  
20
35
 
≥
65
 
LT
 
C
S
 
B
Z
D
 
A
D
 
A
P 
op
io
id
 
+
 
+
 
±
 
+
 
 
 
 
 
 
Et
o 
et
 a
l. 
19
98
 
Ja
pa
n 
53
 
≥
65
 
LT
 
C
S
 
B
Z
D
 
 
 
+
 
 
±
 
 
C
ut
so
n 
et
 a
l. 
19
97
 
U
S
 
12
 
M
ea
n 
70
 
I 
C
O
 
B
Z
D
 (
di
az
ep
am
) 
 
 
 
 
+
 
 
Lo
rd
 e
t 
al
. 
19
95
 
A
us
tr
al
ia
 
41
4 
M
ea
n 
74
 
LT
 
C
S
 
B
Z
D
 
ps
yc
ho
tr
op
ic
s 
≥
1 
A
D
 
 
 
 
 
+
 
±
 
 +
 
+
 
Lo
rd
 e
t 
al
. 
19
92
 
A
us
tr
al
ia
 
10
0 
≥
60
 
LT
 
C
S
 
ps
yc
ho
tr
op
ic
s 
 
 
 
 
+
 
+
 
Pe
nn
in
x 
et
 a
l. 
19
98
 
U
S
 
12
86
 
≥
71
 
LT
 
L 
A
D
 (
m
os
tly
 
am
itr
ip
ty
lin
e)
 
 
 
 
±
 
 
 
D
ra
ga
ni
ch
 e
t 
al
. 
20
01
 
U
S
 
12
 
M
ea
n 
67
 
I 
C
O
 
A
D
s,
 
am
itr
ip
ty
lin
e 
de
si
pr
am
in
e 
pa
ro
xe
tin
e 
 
 
 +
 
±
 
±
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  +
=
po
si
tiv
e 
as
so
ci
at
io
n 
w
ith
 d
ec
lin
e,
 ±
=
 n
o 
as
so
ci
at
io
n,
 (
em
pt
y)
=
 n
ot
 s
tu
di
ed
 o
r 
re
po
rt
ed
. 
 
LT
 =
 lo
ng
-t
er
m
 u
se
, 
I 
=
 in
ci
de
nt
 u
se
 o
r 
si
ng
le
 d
os
e,
 C
O
 =
 c
ro
ss
-o
ve
r 
tr
ia
l, 
L 
=
 lo
ng
itu
di
na
l s
tu
dy
, 
C
S
 =
 c
ro
ss
-s
ec
tio
na
l s
tu
dy
, 
B
Z
D
 =
 b
en
zo
di
az
ep
in
e,
 A
D
 
=
 a
nt
id
ep
re
ss
an
t,
 A
P 
=
 a
nt
ip
sy
ch
ot
ic
,  
A
D
L 
=
 A
ct
iv
iti
es
 o
f 
D
ai
ly
 L
iv
in
g,
 I
A
D
L 
=
 I
ns
tr
um
en
ta
l A
ct
iv
iti
es
 o
f 
D
ai
ly
 L
iv
in
g,
 s
el
f-
re
po
rt
ed
 m
ob
ity
 =
 s
el
f-
re
po
rt
ed
 
di
ff
ic
ul
ty
 o
r 
di
sa
bi
lit
y 
in
 m
ob
ili
ty
, 
m
ob
ili
ty
 p
er
fo
rm
an
ce
 =
 w
al
ki
ng
 s
pe
ed
 o
r 
ca
de
ns
e 
(s
te
ps
/m
in
) 
or
 T
U
G
 t
es
t,
 S
PP
B
 =
 s
ho
rt
 p
hy
si
ca
l p
er
fo
rm
an
ce
 b
at
te
ry
, 
EP
ES
E  
=
 p
hy
si
ca
l p
er
fo
rm
an
ce
 t
es
t 
ba
tt
er
y 
de
ve
lo
pe
d 
fo
r 
th
e 
Es
ta
bl
is
he
d 
Po
pu
la
tio
ns
 f
or
 E
pi
de
m
io
lo
gi
c 
S
tu
di
es
 o
f 
th
e 
El
de
rl
y,
 b
al
an
ce
 =
 b
al
an
ce
 t
es
t 
re
su
lts
, 
in
cl
ud
in
g 
po
st
ur
al
 s
w
ay
 m
ea
su
re
m
en
ts
, 
m
us
cl
e 
st
re
ng
th
 =
 g
ri
p 
st
re
ng
th
, 
an
kl
e 
or
 q
ua
dr
ic
ep
s 
st
re
ng
th
. 
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  Ta
bl
e 
6.
 S
um
m
ar
y 
of
 s
tu
di
es
 r
el
at
ed
 t
o 
an
ti
ps
yc
ho
ti
c 
us
e 
an
d 
m
or
ta
lit
y 
am
on
g 
ol
de
r 
pe
op
le
  
 S
tu
d
y 
D
ru
g
s 
N
 
S
et
ti
n
g
 
A
g
e 
an
d
 g
en
d
er
 
d
is
tr
ib
u
ti
on
 
H
az
ar
d
 r
at
io
(s
),
 o
r 
ot
h
er
 r
is
k 
m
ea
su
re
 
S
uh
 e
t 
al
. 
20
05
 
an
tip
sy
ch
ot
ic
s 
 
27
3 
w
ith
 
de
m
en
tia
 
I 
 
hi
gh
er
 m
or
ta
lit
y 
am
on
g 
no
nu
se
rs
 H
R
 1
.2
8 
(1
.1
3‒
1.
44
) 
co
m
pa
re
d 
to
 A
P 
us
er
s 
 
W
an
g 
et
 a
l. 
20
05
 
an
tip
sy
ch
ot
ic
s,
 
at
yp
ic
al
 v
s.
 
co
nv
en
tio
na
l  
22
 8
90
 in
ci
de
nt
 
us
er
s  
C
 a
nd
 I
 
≥
65
 
co
m
pa
re
d 
to
 a
ty
pi
ca
l A
P 
us
e,
  
co
nv
en
tio
na
l A
P 
H
R
 1
.3
7 
(1
.2
7 ‒
1.
49
),
 
<
40
 d
ay
s 
tr
ea
tm
en
t 
H
R
 1
.5
6 
(1
.3
7‒
1.
78
),
 
40
-7
9 
d 
tr
ea
tm
en
t 
H
R
 1
.3
7 
(1
.1
9‒
1.
59
),
 
80
-1
80
 d
 t
re
at
m
en
t 
H
R
 1
.2
7 
(1
.1
4‒
1.
41
),
 
lo
w
 d
os
e 
(<
m
ed
ia
n)
 H
R
 1
.1
4 
(1
.0
4‒
1.
49
) 
hi
gh
 d
os
e 
(>
m
ed
ia
n)
 H
R
 1
.7
3 
(1
.5
7‒
1.
90
) 
H
ar
tik
ai
ne
n 
et
 
al
. 
20
05
 
an
tip
sy
ch
ot
ic
s 
13
7 
pa
rt
ic
ip
an
ts
 
w
ith
 d
em
en
tia
 
I 
an
d 
C
 
≥
75
 
 
an
tip
sy
ch
ot
ic
 u
se
 H
R
 2
.7
5 
(1
.4
6‒
5.
19
) 
 
co
m
pa
re
d 
to
 n
on
us
er
s 
of
 p
sy
ch
ot
ro
pi
c  
 
(a
dj
us
te
d 
fo
r 
ag
e 
an
d 
ge
nd
er
) 
B
ar
ne
tt
 e
t 
al
. 
20
06
 
an
tip
sy
ch
ot
ic
s 
(a
ty
pi
ca
l, 
co
nv
en
tio
na
l v
s.
 
no
nu
se
rs
 o
f 
A
Ps
, 
A
D
s 
or
 m
oo
d 
st
ab
ili
ze
rs
) 
 
14
05
7 
pa
rt
ic
ip
an
ts
 
w
ith
 p
ne
um
on
ia
 
I 
M
ea
n 
ag
e 
69
 
ye
ar
s,
 9
7%
 m
en
 
(v
et
er
an
s)
 
co
nv
en
tio
na
l A
P 
O
R
 1
.5
1 
(1
.0
4‒
2.
19
) 
fo
r 
in
-h
os
pi
ta
l 
m
or
ta
lit
y ,
 
at
yp
ic
al
 A
P 
no
 a
ss
oc
ia
tio
n 
N
on
in
o 
et
 a
l. 
20
06
 
at
yp
ic
al
 
an
tip
sy
ch
ot
ic
s 
23
14
 
pa
rt
ic
ip
an
ts
 
w
ith
 d
em
en
tia
 
(2
94
 u
se
rs
 w
ith
 
B
PS
D
 a
nd
 2
02
0 
no
nu
se
rs
 a
s 
co
nt
ro
ls
),
  
C
 a
nd
 I
 
≥
65
, 
m
ea
n 
ag
e 
83
 
ye
ar
s,
 7
0 
%
 
w
om
en
  
 
 
at
yp
ic
al
 A
Ps
 H
R
 1
.0
2 
(0
.7
8‒
1.
34
) 
H
ol
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 e
t 
al
. 
20
07
 
an
tip
sy
ch
ot
ic
s 
(i
nd
iv
id
ua
l d
ru
gs
) 
16
 6
34
 in
ci
de
nt
 
us
er
s,
  
98
31
 p
re
va
le
nt
 
us
er
s  
C
 a
nd
 I
 
≥
65
, 
  
su
bg
ro
up
 o
f 
us
er
s 
w
ith
  
de
m
en
tia
 
ch
lo
rp
ro
m
az
in
e 
R
R
 1
.3
9 
(1
.1
5‒
1.
67
),
  
ha
lo
pe
ri
do
l R
R
 2
.2
6 
(2
.0
8 ‒
2.
47
),
 
ri
sp
er
id
on
e 
R
R
 1
.2
3 
(1
.0
7‒
1.
40
),
 
m
ul
tip
le
 s
tu
dy
 d
ru
gs
 R
R
 1
.4
8 
(1
.1
0‒
1.
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) 
fo
r 
in
ci
de
nt
 
A
P 
us
e 
co
m
pa
re
d 
to
 o
la
nz
ap
in
e 
us
e 
R
ai
vi
o 
et
 a
l. 
20
07
 
an
tip
sy
ch
ot
ic
s,
 
at
yp
ic
al
 v
s.
 
co
nv
en
tio
na
l 
25
4 
w
ith
 
de
m
en
tia
 
I 
M
ea
n 
ag
e 
86
 
 
at
yp
ic
al
 H
R
 0
.4
9 
(0
.2
4‒
0.
99
) 
co
nv
en
tio
na
l H
R
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.6
8 
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.4
6 ‒
1.
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et
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an
d
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en
d
er
 
d
is
tr
ib
u
ti
on
 
H
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ar
d
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at
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(s
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ot
h
er
 r
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re
 
S
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ne
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ei
ss
 e
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al
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20
07
 
an
tip
sy
ch
ot
ic
s,
 
at
yp
ic
al
 v
s.
 
co
nv
en
tio
na
l  
37
 2
41
 in
ci
de
nt
 
us
er
s 
 
(t
he
 s
am
e 
st
ud
y 
sa
m
pl
e 
as
 in
 
S
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og
uc
hi
)  
C
 a
nd
 I
 
≥
65
 
 
C
on
ve
nt
io
na
l v
s.
 a
ty
pi
ca
l:
  
m
or
ta
lit
y 
ra
tio
 1
.3
2 
(1
.2
3 ‒
1.
42
) 
in
 1
80
 d
, 
 
hi
gh
 d
os
e 
m
or
ta
lit
y 
ra
tio
 1
.6
7 
(1
.5
0‒
1.
86
),
  
du
ri
ng
 f
ir
st
 4
0 
d 
of
 t
re
at
m
en
t 
m
or
ta
lit
y 
ra
tio
 1
.6
0 
(1
.4
2‒
1.
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H
al
op
er
id
ol
 m
or
ta
lit
y 
ra
tio
 2
.1
4 
(1
.8
6‒
2.
45
) 
co
m
pa
re
d 
to
 r
is
pe
ri
do
ne
 
K
al
es
 e
t 
al
. 
20
07
 
an
ti
ps
yc
ho
tic
s 
vs
. 
ot
he
r 
ps
yc
hi
at
ri
c 
m
ed
ic
at
io
ns
 
10
 6
15
 in
ci
de
nt
 
us
er
s,
 w
ith
 
de
m
en
tia
 
C
 
≥
65
 
 
hi
gh
er
 m
or
ta
lit
y 
ra
te
 a
m
on
g 
A
P 
us
er
s 
co
m
pa
re
d 
to
 u
se
rs
 
of
 o
th
er
 p
sy
ch
ia
tr
ic
 m
ed
ic
at
io
ns
, 
 
co
m
pa
re
d 
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 c
on
ve
nt
io
na
l A
Ps
; 
 
at
yp
ic
al
 A
Ps
 R
R
 0
.9
3 
(0
.7
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1.
16
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at
yp
ic
al
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 c
on
ve
nt
io
na
l A
P 
R
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 1
.3
3 
(0
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4‒
1.
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an
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vu
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an
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 R
R
 0
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9 
(0
.5
1‒
1.
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S
S
R
Is
 R
R
 0
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9 
(0
.3
9‒
0.
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ot
he
r 
2n
d  
ge
n 
A
D
s 
R
R
 0
.6
0 
(0
.4
6‒
0.
79
) 
Tr
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rò
 e
t 
al
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20
07
 
an
tip
sy
ch
ot
ic
s,
 
at
yp
ic
al
 v
s.
 
co
nv
en
tio
na
l 
23
85
 
C
 
≥
65
 
A
ty
pi
ca
l A
Ps
 O
R
 2
.2
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1.
2‒
3.
9)
, 
 
co
nv
en
ti
on
al
 A
Ps
 O
R
 1
.7
 (
1.
3‒
2.
2)
 v
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 n
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us
er
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n 
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yp
ic
al
 a
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 c
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ve
nt
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na
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Ps
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 e
t 
al
. 
20
07
 
an
tip
sy
ch
ot
ic
s 
(a
ty
pi
ca
l v
s.
 
co
nv
en
tio
na
l)
 
27
 2
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 m
at
ch
ed
 
pa
ir
s,
 w
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de
m
en
tia
, 
in
ci
de
nt
 u
se
rs
 
C
 a
nd
 I
 
≥
66
 
A
ty
pi
ca
l A
P 
30
 d
 H
R
 1
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1 
(1
.0
2‒
1.
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) 
am
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g 
co
m
m
un
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lin
g 
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A
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pi
ca
l A
P 
30
 d
 H
R
 1
.5
5 
(1
.1
5‒
2.
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g 
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C
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de
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vs
. 
no
nu
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f 
A
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, 
C
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ve
nt
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na
l A
P 
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 d
 H
R
 1
.5
5 
(1
.1
9‒
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) 
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g 
C
D
-
pe
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s,
 
C
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ve
nt
io
na
l A
P 
30
 d
 H
R
 1
.2
6 
(1
.0
4‒
1.
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) 
am
on
g 
LT
C
 
re
si
de
nt
s 
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. 
at
yp
ic
al
 A
P 
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S
et
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uc
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 e
t 
al
. 
20
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an
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ot
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s,
 
at
yp
ic
al
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s.
 
co
nv
en
tio
na
l  
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41
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ci
de
nt
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er
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C
 a
nd
 I
 
≥
65
 
 
an
tip
sy
ch
ot
ic
 u
se
 H
R
 1
.2
7 
(1
.1
8‒
1.
37
) 
fo
r 
al
l n
on
-
ca
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er
 d
ea
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s 
du
ri
ng
 1
80
 d
, 
 
co
nv
en
tio
na
l A
P 
H
R
 1
.2
3 
(1
.1
0‒
1.
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) 
fo
r 
ca
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va
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ul
ar
 
de
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h 
an
d 
H
R
 1
.3
6 
(1
.1
9‒
1.
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) 
fo
r 
ou
t 
of
 h
os
pi
ta
l d
ea
th
 
du
ri
ng
 1
80
 d
 v
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 a
ty
pi
ca
l A
P 
us
e 
Ta
bl
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on
tin
ue
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S
tu
d
y 
D
ru
g
s 
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S
et
ti
n
g
 
A
g
e 
an
d
 g
en
d
er
 
d
is
tr
ib
u
ti
on
 
H
az
ar
d
 r
at
io
(s
),
 o
r 
ot
h
er
 r
is
k 
m
ea
su
re
 
B
al
la
rd
 e
t 
al
. 
20
09
 
an
tip
sy
ch
ot
ic
s,
 
w
ith
dr
aw
al
 t
ri
al
 
(h
al
f 
ra
nd
om
iz
ed
 
to
 c
on
tin
ue
 A
Ps
, 
ha
lf 
to
 p
la
ce
bo
) 
12
8 
I 
M
ea
n 
ag
e 
85
 
ye
ar
s,
 d
em
en
tia
 
C
um
ul
at
iv
e 
pr
ob
ab
ili
ty
 o
f 
su
rv
iv
al
 d
ur
in
g 
12
 m
on
th
s 
 
70
%
 f
or
 A
P 
gr
ou
p 
an
d 
77
%
 f
or
 p
la
ce
bo
 g
ro
up
, 
lo
g -
ra
nk
 
p=
0.
03
 
 
Li
pe
ro
ti 
et
 a
l. 
20
09
 
an
tip
sy
ch
ot
ic
s,
 
co
nv
en
tio
na
l v
s.
 
at
yp
ic
al
, 
 
ha
lo
pe
ri
do
l v
s.
 
ri
sp
er
id
on
e 
65
24
 in
ci
de
nt
 
at
yp
ic
al
 A
P 
us
er
s,
 1
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1 
in
ci
de
nt
 
co
nv
en
tio
na
l A
P 
us
er
s  
w
ith
 d
em
en
tia
 
I 
M
ea
n 
ag
e 
84
, 
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%
 
w
om
en
 
C
on
ve
nt
io
na
l A
P 
H
R
 1
.2
6 
(1
.1
3‒
1.
42
) 
vs
. 
at
yp
ic
al
 A
P 
us
e.
 
H
al
op
er
id
ol
 H
R
 1
.3
1 
(1
.1
3‒
1.
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) 
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. 
ri
sp
er
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e.
  
R
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k 
w
ith
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ic
al
 A
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=
 r
is
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ri
do
ne
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R
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i-
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l. 
20
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an
tip
sy
ch
ot
ic
s 
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I 
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9 
pa
rt
ic
ip
an
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<
65
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, 
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≥
65
, 
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%
 w
om
en
 
±
 m
or
ta
lit
y 
H
R
 0
.8
3 
(0
.6
9‒
1.
00
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R
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so
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 e
t 
al
. 
20
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lo
pe
ri
do
l, 
ol
an
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, 
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et
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, 
ri
sp
er
id
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e  
90
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(1
81
27
 e
xp
os
ed
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 A
Ps
) 
w
i t
h 
de
m
en
tia
 
C
 a
nd
 I
 
≥
65
, 
ab
ou
t 
98
%
 
m
en
 (
ve
te
ra
ns
)  
ha
lo
pe
ri
do
l >
1 
m
g 
H
R
 3
.2
 (
2.
2‒
4.
5)
, 
ol
an
za
pi
ne
 >
2,
5 
m
g 
H
R
 1
.5
 (
1.
1‒
2.
0,
 
qu
et
ia
pi
ne
 >
50
 m
g 
no
 a
ss
oc
ia
tio
n,
 
ri
sp
er
id
on
e 
>
1 
m
g 
H
R
 1
.6
 (
1.
1‒
2.
2)
, 
 
du
ri
ng
 t
he
 f
ir
st
 3
0 
da
ys
 o
f 
dr
ug
 u
se
  
(n
o 
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so
ci
at
io
ns
 a
ft
er
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0 
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ys
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M
us
ic
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 e
t 
al
. 
20
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an
tip
sy
ch
ot
ic
s 
(c
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ve
nt
io
na
l, 
at
yp
ic
al
) 
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 w
ith
 
de
m
en
tia
 
 
≥
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m
ea
n 
ag
e 
79
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ar
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 w
om
en
 
C
on
ve
nt
io
na
l A
P 
H
R
 3
.7
 (
2.
6‒
5.
1)
, 
 
at
yp
ic
al
 A
P 
H
R
 2
.5
 (
2.
0 ‒
3.
0)
 v
s.
 n
on
us
e 
of
 A
Ps
, 
C
on
ve
nt
io
na
l v
s.
 a
ty
pi
ca
l H
R
 1
.5
 (
1.
1‒
2.
1)
 
K
al
es
 e
t 
al
. 
20
12
 
an
tip
sy
ch
ot
ic
s 
an
d 
va
lp
ro
ic
 a
ci
d 
33
60
4 
in
ci
de
nt
 
us
er
s 
w
ith
 
de
m
en
tia
 
C
 
≥
65
 y
ea
rs
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lo
pe
ri
do
l R
R
 1
.5
4 
(1
.3
8‒
1.
73
),
 
ol
an
za
pi
ne
 R
R
 0
.9
9 
(0
.8
9 ‒
1.
10
),
 
va
lp
ro
ic
 a
ci
d 
R
R
 0
.9
1 
(0
.7
8‒
1.
06
),
  
vs
. 
ri
sp
er
id
on
e 
du
ri
ng
 f
ir
st
 1
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 d
 
In
cl
us
io
n 
cr
ite
ri
a:
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ss
oc
ia
tio
n 
be
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ee
n 
dr
ug
s 
w
ith
 s
ed
at
iv
e 
pr
op
er
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s 
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d 
m
or
ta
lit
y 
(a
dj
us
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d 
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r 
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va
ri
at
es
),
 o
ld
er
 p
eo
pl
e 
(≥
65
) 
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 p
er
so
ns
 w
it
h 
de
m
en
tia
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ig
in
al
 s
tu
di
es
. 
H
az
ar
d 
ra
tio
 o
r 
re
la
tiv
e 
ri
sk
 is
 r
ep
or
te
d 
fo
r 
al
l-
ca
us
e 
m
or
ta
lit
y 
if 
no
t 
ot
he
rw
is
e 
in
di
ca
te
d 
(w
ith
 9
5%
 c
on
fid
en
ce
 in
te
rv
al
).
 
±
 =
 n
o 
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so
ci
at
io
n,
 +
 =
 p
os
iti
ve
 a
ss
oc
ia
tio
n 
w
ith
 m
or
ta
lit
y,
 I
 =
 in
st
itu
tio
na
l c
ar
e 
(s
et
tin
g)
, 
C
 =
 c
om
m
un
it
y-
dw
el
lin
g 
(s
et
tin
g)
, 
H
R
 =
 h
az
ar
d 
ra
tio
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R
R
 =
 
re
la
tiv
e 
ri
sk
, 
A
P=
an
tip
sy
ch
ot
ic
, 
 A
D
 =
 a
nt
id
ep
re
ss
an
t,
 S
S
R
I 
=
 s
el
ec
tiv
e 
se
ro
to
ni
n 
re
up
ta
ke
 in
hi
bi
to
r,
 B
PS
D
 =
 b
eh
av
io
ra
l a
nd
 p
sy
ch
ia
tr
ic
 s
ym
pt
om
s 
of
 
de
m
en
tia
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=
 d
ay
s,
 y
 =
 y
ea
rs
, 
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C
 =
 lo
ng
-t
er
m
 c
ar
e,
 C
D
=
 c
om
m
un
ity
-d
w
el
lin
g.
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 t
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 m
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 d
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0‒
1.
22
),
 
S
S
R
Is
 H
R
 1
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de
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ra
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 d
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n
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 m
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 d
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 1
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 f
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3 Aims of the thesis 
The overall aim of this thesis was to investigate the association between sedative load and 
adverse events among community-dwelling people aged 75 years and older. 
 
The specific aims of this study were to investigate the: 
 
1. prevalence of sedative load among community-dwelling older people and 
determine factors associated with sedative load; 
2. association between the sedative load and objective measures of balance and 
mobility; 
3. association between sedative load and objective measures of muscle strength; and 
4. evolution of sedative load over the study period and the corresponding risk of 
death. 
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4 Materials and methods 
4.1 STUDY POPULATION 
Studies presented in the thesis utilized data collected as a part of Geriatric 
Multidisciplinary Strategy for Good Care of the Elderly (GeMS) Study. The GeMS Study 
was a randomized comparative study that evaluated a model for geriatric assessment, care 
and rehabilitation. A random sample of 1000 people aged 75 years and older (born before 
November 1, 1928) and inhabitants of city of Kuopio, Finland, were invited to participate. 
In the beginning of 2004, the city of Kuopio had a population of 88,253 inhabitants, 5,615 of 
whom were aged ≥75 years. 
In the GeMS Study, 500 persons were randomized to an intervention group and 500 to a 
comparison group. Of 1000 people, 781 provided written informed consent to participate, 
162 refused participation, 2 relocated and 55 died before the baseline examination. 
Participants living in institutional care (n=81) were excluded from the analyses and thus, 
700 community-dwelling participants were included at the baseline (Figure 1).  
The baseline examination took place in 2004 followed by annual examinations until 
2007. In Studies I‒III, only baseline data were analyzed. In Study IV, the evolution of 
sedative load was analyzed utilizing data from all examinations.  
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Population
People aged ≥75 years living in Kuopio
N=5615 (1 January, 2004)
Random sample n=1000
(1 November, 2003)
Intervention group, n=500
Comparison group, n=500
Baseline 2004
Intervention group, n=404
Comparison group, n=377
1. Follow-up 2005
Intervention group, n=371
Comparison group, n=346
2. Follow-up 2006
Intervention group, n=339
Comparison group, n=318
3. Follow-up 2007
Intervention group, n=315
Comparison group, n=294
Not examined
Refused n=162
Died n=55
Moved n=2
Loss to follow-up
Refused n=11
Died n=52
No contact n=1
Loss to follow-up
Refused n=4
Died n=55
Moved n=1
Loss to follow-up
Refused n=2
Died n=46
 
 
Figure 1. The flow chart of the GeMS Study 
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4.2 DATA COLLECTION 
One of three trained nurses conducted annual, structured interviews for each participant to 
assess sociodemographic factors, health status and drug use. Sociodemographic factors 
included living situation (alone versus with someone else), years of education, and use of 
home-nursing services or other help. Health status included diagnosed diseases, self-rated 
health, and tests including the Mini-Mental State Examination (MMSE), the Geriatric 
Depression Scale (GDS15), and IADL scale. Participant self-reported diagnoses were 
verified from medical records from municipal health centers, home nursing service, local 
hospitals and the Kuopio University Hospital. 
4.2.1 Medication exposure assessment 
During the annual interviews by study nurses, participants were asked which prescription 
and over-the-counter drugs they used over a two-week period. Participants were asked to 
bring their prescription forms and drug packages to the interview. Patterns of drug use 
were also assessed in terms of regular and when-required drug use. A regular pattern of 
drug use was defined as a drug taken daily or at regular intervals. Drug use was defined as 
regular if participant took the drug ≥4 times a week. For long-acting intramuscular 
antipsychotics, regular use was considered when drug was taken at regular intervals from 
once-a-week to once-a-month. Drug use was considered when-required if there was an 
irregular pattern of use according to the participant’s self-report. If a participant had a 
prescription from, drug package or medical record that suggested they took a drug that 
they did not self-report, then the nurse interviewer specifically asked about the use of this 
drug over the previous two weeks. Thus, medical records were used as one data source and 
as a basis for discussion with a participant on his or her actual drug use patterns. 
4.2.2 Physical function tests 
Physical function tests and interview about physical activity were conducted by two 
trained physiotherapists, and performed one-to-two weeks after each participant’s nurse 
interview. The interview by the physiotherapist included an assessment of current physical 
activity (for example, Grimby scale), and problems in mobility. Medical records were also 
one data source in physiotherapist interview. The physical function testing was conducted 
in the outpatient clinic at the municipal health centre. The tests included mobility and 
balance tests, postural sway and muscle strength testing. If the participant was unable to 
visit the outpatient clinic, the measurements took place in the participant’s home. In-home 
testing included only the grip strength test, and chair stands if a participant had a standard 
chair for the testing. Other tests were only conducted in the outpatient clinic to ensure a 
standard environment and reliability and validity of measurements. 
4.2.3 Intervention and Comprehensive Geriatric Assessment 
The intervention conducted by a multidisciplinary team was aimed at preventing disability 
among participants, and the CGA was an integral part of the intervention. The intervention 
was individually tailored, and consisted of a medical and a physical activity component. 
The medical component of the intervention included a structured clinical examination and 
medication assessment conducted by two physicians who were trainees in geriatrics. The 
physical activity component consisted of individually tailored physical activity counseling 
and an opportunity to participate in group-based muscle strength and balance training 
once a week at a gym that was supervised by physiotherapists. Participants in the 
intervention group also received advice from the other members of CGA team including 
dentists, ophthalmologist (only in 2006) and a nutritionist (Lampela et al. 2007, Rikala et al. 
2011). The intervention focused on health and physical function related problems that a 
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participant had, including medical problems, medication-related problems, malnutrition, 
declined cognition, and declined physical health (Lihavainen et al. 2011).  
One objective of the intervention was to identify and address the use of potentially 
inappropriate drugs, adverse drug events and drug-drug interactions (Lampela et al. 2011, 
Rikala et al. 2011). The assessment and optimization of medications was conducted by 
study physicians. Psychotropic drug use was one focus area of the medication review in the 
CGA (Rikala et al. 2011). The particular focus areas were: determination if there was current 
indication for psychotropic drug use, use of antipsychotics among participants with 
dementia but without current psychotic symptoms or aggression, sub-optimal use of 
antidepressants among those with depressive symptoms, regular and long-term 
benzodiazepine use, concomitant use of two or more psychotropic drugs, inappropriate 
doses, and potentially inappropriate use of specific drugs (tricyclic antidepressants for 
depression and use of long-acting benzodiazepines). In the intervention group, nurses 
acted as case managers organizing care and services, and giving counseling and support for 
family members.   
Participants in both groups received standard care during the study. However, 
physicians referred participants in the intervention group to special health care if they 
identified a need for this. Thus, it is possible that after the baseline, the intervention group 
may have had more accurately diagnosed diseases than the comparison group. 
In Study IV, the intervention and comparison groups were analyzed together. This was 
because the intervention did not impact the evolution of psychotropic drugs, and no 
differences in psychotropic drug utilization were observed between the intervention and 
comparison groups (Rikala et al. 2011). In addition, tests were conducted to observe the 
possible differences in the utilization patterns of sedative drugs during the study but none 
were found. Mortality rates between the groups were also similar. For these reasons, both 
intervention and comparison groups were analyzed together.  
4.3 SEDATIVE LOAD 
4.3.1 Calculation of sedative load 
Sedative load was calculated according to the previously published Sedative Load Model 
(Linjakumpu et al. 2003, Linjakumpu et al. 2004). The Sedative Load Model considers four 
groups of drugs with sedative properties but only two groups are considered when 
assigning sedative ratings to drugs and calculating sedative load. The model was created 
by categorizing all drugs marketed in Finland between 1998 and 2001 according to their 
sedative potential. The categorization was based on consensus between a 
psychogeriatrician, a geriatrician and a physician specialized in pharmacoepidemiology. 
The basis of categorization was manufacturers’ summaries of product characteristics.  
Drugs in group one included primary sedatives and were assigned a sedative rating of 2 
(Table 8). Drugs in group two included drugs with sedation as prominent side effect and 
preparations with a sedating component, and were assigned a sedative rating of 1. Group 
three included drugs with sedation as a potential side effect (e.g. acetyl-cholinesterase 
inhibitors, second generation antihistamines). Group-four included all other drugs with no 
known sedative properties. In Studies II‒IV, only regularly used drugs were considered 
when sedative load was calculated. In Study I, two different sedative loads were calculated; 
regular sedative load (considering sedative ratings from regularly used drugs only), and 
total sedative load (considering both sedative ratings of regular and when-required drugs). 
In Study I, when-required drugs were assigned with a sedative rating of 0.5 regardless of 
whether they were group 1 or 2 sedative drugs. In addition, regular sedative load of the 
population was defined as the sum of sedative ratings at a population level considering 
regularly used drugs. 
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Sedative load was assessed in annual examinations during 2004-2007. For Studies I-III, 
only baseline sedative load was considered. In Study IV, exposure to drugs with sedative 
properties was defined as time-varying sedative load to take account on possible changes in 
drug use in each examination year.  
 
Table 8. Drugs contributing to sedative load, according to the Sedative Load Model 
 
Drug group Examples 
Group 1. Primary sedatives (sedative rating 2) 
Conventional antipsychotics (N05A) phenothiazines, butyrophenones, thioxanthenes, 
sulpride, lithium 
Anxiolytics (N05B) benzodiazepines, hydroxyzine 
Hypnotics and sedatives (N05C) benzodiazepines, zopiclone, zolpidem, zaleplon, 
valerian, clometiazole 
Antidepressants (N06AA, N06C)  
- tricyclic antidepressants, non-selective 
 monoamine reuptake inhibitors 
clomipramine, trimipramine, nortriptyline, doxepin, 
amitriptyline 
- second generation antidepressants mianserin 
- combinations amitriptyline with chlordiazepoxide or perphenazine 
Group 2. Drugs with sedation as a prominent side effect or preparations with a sedating 
component (sedative rating 1) 
CNS (N)  
- opioids (N02A) morphine, oxycodone, codeine, buprenorphine, 
tramadol, fentanyl, paracetamol with codeine 
- antiepileptics (N03A) hydantoin derivatives, carbamazepine and 
derivatives, valproic acid, gabapentin, clonazepam, 
lacosamide, lamotrigine, levetiracetam, pregabaline, 
tiagabine, topiramate, zonisamide 
- anticholinergic anti-parkinson drugs biperiden 
- atypical antipsychotics clozapine, olanzapine, quetiapine, risperidone, 
aripiprazole, ziprasidone 
- SSRIs (N06AB) fluoxetine, fluvoxamine, paroxetine, sertraline, 
citalopram, escitalopram 
- other second generation antidepressants trazodone, nefazodone, mirtazapine, venlafaxine, 
milnacipran, duloxetine 
- dopamine agonists (N04BC) pramipexole, ropinirole, rotigotine, pergolide 
- drugs for migraine, incl. psychotropics meprobamate with ergot alkaloid, metoclopramide 
with ASA, triptans 
Alimentary (A)  
- propulsives, antiemetics metoclopramide, scopolamine 
- antispasmodics with psychotropics diazepam with glycopyrronium, chlordiazepoxide 
with klidin, oxazepam with ambutonium 
Genito-urinary (G)  
- drugs for erection disturbances incl. 
 psychotropics 
meprobamate with testosterone and yohimbine (not 
on market anymore) 
Musculo-skeletal (M)  
- NSAIDs indometacin (with ethylmorphine), ibuprofen with 
codeine 
- centrally acting muscle relaxants, incl. 
 psychotropics 
meprobamate or diazepam with kinin, orphenadrine, 
baclofen, tizanidine 
Respiratory (R)  
- old antihistamines (in combinations) cinnarizine or carbinoxamine with systemic nasal 
decongestants 
- xanthenes theophylline and its combinations 
- antitussives with sedating components bromhexine, ethylmorphine, codeine 
- antiemetics or drugs for dizziness, incl. 
psychotropics 
cyclizine (with diazepam), meclozine 
Ophthalmologicals (S)  
- anticholinergic drops for eyes scopolamine 
CNS = central nervous system, SSRIs = selective serotonin reuptake inhibitor, NSAIDs = non-steroidal 
anti-inflammatory drugs, ASA = acetyl salisylic acid. 
Adapted according to Linjakumpu et al. 2003, with additions made in Taipale et al. 2011 Drugs Aging 
 
 
  
37 
 
 
Sedative load was calculated by summing the sedative ratings for all drugs used by the 
participants according to the formula: 
 
Sedative load =σ ܴܵ௞௡௞ୀଵ           
 
Where n stands for the number of drugs and SRk indicates the sedative rating for drug k. 
 
The Sedative Load Model was updated in Study I to include drugs that were marketed in 
Finland since the development of the original model. To update the model one clinical 
pharmacist reviewed the summary of product characteristics (SPCs) and research literature 
for all new drugs marketed in Finland from 2001 until the end of 2009. Based on these data 
a geriatrician, a geriatrician specialized in geriatric pharmacotherapy and two clinical 
pharmacists independently assigned sedative ratings for each new drug. The four member 
expert panel then met and any discrepancies were resolved through discussion. All new 
drugs were categorized using their Anatomical Therapeutic Chemical (ATC) code. As a 
result of this update, 15 new drugs were added to Group-two of the sedative load model: 
aripiprazole, ziprasidone, duloxetine, pramipexole, ropinirole, rotigotine, pergolide, 
clonazepam, lacosamide, lamotrigine, levetiracetam, pregabaline, tiagabine, topiramate and 
zonisamide (Table 8).  
4.3.2 Drug classification 
All drugs used by the participants were classified using the ATC classification system 
recommended by the World Health Organization (WHO). The ATC classification system is 
a hierarchical classification based on the organ or system on which they act and their 
therapeutic, pharmacological and chemical properties. The classification includes five 
different levels, from the organ or system (main group) to pharmacological/ therapeutic 
subgroups, and towards the chemical substance (fifth level).  
For the purpose of calculating sedative load, the following definitions were made. 
‘Atypical antipsychotics’ were defined as clozapine, quetiapine, olanzapine, risperidone, 
ziprasidone and aripiprazole. ‘Conventional antipsychotics’ were deemed to include all 
other drugs in ATC group N05A excluding lithium. ‘Tricyclic antidepressants’ were 
defined as ATC class, N06AA, ‘SSRIs’ as N06AB, and ‘other antidepressants’ as 
moclobemide and N06AX.   
4.4 OUTCOME MEASURES 
4.4.1 Balance and mobility tests (II) 
Maximal walking speed (m/s) was measured over a 10 m distance. In all timed tests, time 
was taken using a stopwatch. Participants were allowed three meters for acceleration before 
the start line and then they were encouraged to walk as fast as possible within the confines 
of their current health. Participants wore their regular footwear and were allowed to use a 
walking aid in the walking speed and in the TUG test.   
The TUG Test was used to assess both balance and basic mobility (Podsiadlo et al. 1991). 
The participants were instructed to stand up from a chair, walk for a distance of 3 m at 
maximal speed, turn, walk back, and sit down on the chair. The chair was a standard chair 
with armrests, and participants were allowed to use their arms for support and to assist in 
rising if needed. The time taken was used as a measure of performance.  
The Berg Balance Scale is a test of balance rated by an observer (Berg et al. 1992). The BBS 
consists of 14 different balance tasks related to standing, reaching, bending, turning and 
transferring abilities. Each of the 14 items was scored on scale from 0 (incapable) to 4 (safe 
and independent) by physiotherapist. The overall test score from the BBS ranged from 0 
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(severely impaired) to 56 points (excellent balance). The score reflects a participant’s ability 
to accomplish specific movements and the length of time each of the positions are held.  
In the interview conducted by one of the study nurses, participants were asked to 
evaluate their ability to walk 400 meters on a four-point scale with the following options; 
“no”, “not without help”, “yes with difficulty but without help”, or “yes”. For the purposes 
of the analyses, the categories “not being able” and “not without help” were combined to 
be “no” and others were combined to “yes”. Thus, the variable was treated as self-reported 
ability to walk independently 400 meters (yes/no). 
4.4.2 Muscle strength tests (III) 
Grip strength was measured using a Saehan dynamometer (Saehan Corporation, South 
Korea). Participants were allowed to make one maximal effort with both hands and the best 
result of these attempts was used in analyses. Grip strength was measured in kilograms.  
Knee extension strength was measured using an adjustable dynamometer chair (Good 
Strength, Metitur Oy, Palokka Finland). Participants were tested on both legs and allowed 
to make three maximal efforts with both legs, and the best result of these six attempts was 
used in the analyses. Knee extension strength was measured in newtons.  
The chair stands test was a modified version of Five Chair Rise test (Guralnik et al. 1994). 
The test assessed the ability to perform sit-to-stand and stand-to-sit transfer. Participants 
were instructed to stand up and sit down five times as fast as possible starting in the sitting 
position and stopping after the fifth rise. As a modification of the original test, hands were 
held free on the sides and participants were allowed to help with their hands if needed. 
Performance in the chair stands test was measured as the time taken to complete the test in 
seconds.  
4.4.3 Mortality (IV) 
Mortality data were obtained from the Social Insurance Institution of Finland. The SII 
registers are updated daily using the Population Information System maintained by the 
Population Register Centre of Finland. The date of death for each participant who died 
during the follow-up period was ascertained. 
4.5 COVARIATES AND OTHER MEASURES 
4.5.1 Sociodemographic characteristics 
Self-reported years of education were categorized into two groups (06 and >6 years). 
Marital status was grouped as married, widowed, divorced or never-married. Loneliness 
was defined by asking that “how often do you feel lonely” (never, sometimes, often). 
Alcohol use was defined using two different items; “do you use alcohol” (yes or no), and 
“do you use alcohol for medicinal purposes” (yes or no). A participant was considered an 
alcohol user if they answered yes to either question.  
4.5.2 Health-related characteristics 
Physical activity was assessed using a modified version of the Grimby scale (Grimby 1986). 
Participants were categorized as inactive (no other exercise, light walking 12 times a 
week), moderately active (light walking or other light exercise ≥3 times a week or moderate 
exercise 12 times a week), or active (moderate to vigorous exercise several times a week).  
Self-rated health was determined with 5-point scale (from very poor to very good). For 
the purpose of the analysis, the categories “very poor” and “poor” were combined as 
“poor” and other categories were combined under single category “average or good”.  
The Mini-Mental State Examination was utilized to evaluate cognitive function (Folstein 
et al. 1975, Crum et al. 1993). MMSE scores <25 were considered indicative of cognitive 
impairment (Dahl et al. 2007).  
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Each participants’ comorbidities were scored according to a modified version of the 
Functional Comorbidity Index (FCI) (Groll et al. 2005) which was developed to predict 
physical function in older people. The diagnoses that were included in the FCI were 
arthritis (rheumatoid arthritis and other connective tissue disorders), osteoporosis, asthma/ 
COPD, coronary artery disease, congestive heart failure, myocardial infarction, Parkinson’s 
disease, stroke, diabetes mellitus, depressive symptoms (assessed using the Geriatric 
Depression Scale (Yesavage et al. 1983) with GDS scores ≥5 considered indicative of 
depressive symptoms), visual impairment, hearing impairment, and obesity (body mass 
index >30). For the purposes of the analyses, FCI was classified into 3 groups: 0, 12 and ≥3.  
Dementia was diagnosed as Alzheimer’s disease, vascular dementia or dementia due to 
other general medical conditions according to DSM-IV criteria (American Psychiatric 
Association 1994). Dementia with Lewy bodies was clinically diagnosed according to the 
core criteria published by McKeith et al (McKeith et al. 1996) 
Performance in the IADLs was assessed by the 8-item scale developed by Lawton and 
Brody (Lawton and Brody 1969).  The IADL scale includes activities such as using a 
telephone, shopping, making food, housekeeping activities, and ability to take 
responsibility for own medications and finance. For the purpose of the thesis, participants 
with IADL scores of 0‒6 were defined as having impaired IADL whereas participants with 
scores of 7‒8 were defined as having normal function.  
4.6 STATISTICAL ANALYSIS 
Data analyses were performed using SAS software (version 9.2, SAS Institute, Cary, NC, 
USA), and SPSS software version 17.0 (SPPS Inc, Chicago, Illinois, USA). 
Characteristics of the study sample were summarized using means, percentages and 
standard deviations (SDs). Characteristics of participants were compared with chi-square 
test for categorical variables and analysis of variance (ANOVA) for continuous variables. 
For Studies IIIV, sedative load was categorized as nonusers of sedatives (sedative 
load=0), those having a sedative load of 1‒2 and those with a sedative load of ≥3. In Studies 
II and IV, subgroup analysis were conducted between nonusers of sedatives (sedative 
load=0) and users of sedatives (sedative load >0). In Study I, comparisons were made 
between those with sedative load ≥2 and those with sedative load from 0 to 1.  
For Study I, logistic regression models were used to investigate the univariate and 
multivariate associations between sociodemographic and diagnostic characteristics and 
sedative load. Sociodemographic and health-related factors that were included in the 
multivariate analyses were age, gender, alcohol use, self-rated health, IADL, dementia, 
loneliness, and cardiovascular disease. These factors were selected based on previous 
research on factors associated with psychotropic drug use, and because of being 
significantly associated with sedative load of ≥2 in the univariate analysis. Two logistic 
regression models were computed: one with regular sedative load and another with total 
sedative load. The results of these models were expressed as ORs with 95% confidence 
intervals (CI). 
For Studies II and III, unadjusted and adjusted analysis of covariance (ANCOVA) were 
performed to compare physical function outcome variables between nonusers of sedatives 
(sedative load=0) with those having a sedative load of 1‒2 and those with a sedative load of 
≥3. Models were adjusted for clinically important covariates that may influence the 
relationship between increasing sedative load and physical performance measures. These 
covariates were age (7579, 8084, ≥85 years), gender, education (06, >6 years), Grimby 
Scale, comorbidities using the modified FCI (0, 12, ≥3) and cognitive impairment (MMSE 
<25). A log 10 transformation was performed to improve the normality of the chair stands 
test distribution. For the chair stands test, the values presented are the back-transformed. 
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For Study II, unadjusted and adjusted logistic regression analyses were used to test the 
ability to walk independently 400 meters (yes, no) between nonusers of sedatives (sedative 
load=0) and users of sedatives (sedative load >0). Logistic regression analyses were 
reported using ORs and 95% CIs. Adjustments were made the same covariates as in the 
ANCOVA models. 
For Study IV, differences in sedative drug use between intervention and control groups 
were measured using Mann-Whitney U test and calculating 95% confidence intervals for 
mean sedative loads in both groups. Both tests showed that there were no differences 
between the groups. A Wilcoxon signed rank test was used to show that among users of 
sedatives, the mean sedative load increased significantly from 2004 to 2007 in both groups. 
Thus, group status was not included in the Cox models. 
For Study IV, Cox proportional hazards analysis was used to study sedative load and the 
corresponding risk of death. Sedative load was entered as time-dependent variable in the 
model. Individual exposure times were calculated for each participant according to their 
annual examination dates. The model was adjusted for the following covariates measured 
at the baseline: age (7579, 8084, ≥85 years), sex, FCI score (0, 12, ≥3), dementia, education 
(06, >6 years), and IADL score (06, 78). Deaths were ascertained from the SII until 
December 31, 2008 after which the analyses were censored. Participants were censored at 
the end of next year from their last examination so that they had the maximum possibility 
to participate in the following examination. The results of these models were expressed as 
hazard ratios (HRs) with 95% CIs. 
 
4.7 ETHICAL CONSIDERATIONS 
All participants or their proxies gave written informed consent to participate in the study. 
The study was approved by the Research Ethics Committee of the Northern Savo Hospital 
District, Kuopio, Finland. The study was conducted in accordance with World Medical 
Association Declaration of Helsinki (World Medical Association). Data collected in the 
GeMS Study was stored in a secure and locked file. Data analyses were performed using 
de-identified data only and all researchers signed data usage agreements with the 
University of Eastern Finland. Reports include only grouped data so that no individual 
participant can be identified. 
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5 Results 
5.1 PREVALENCE OF SEDATIVE LOAD IN THE BASELINE 
5.1.1 Description of the study sample 
The majority of the participants were women (69%, n=486) (Table 9). The mean age of the 
700 participants was 81.3 (SD 4.6) years (Table 10). The prevalence of cognitive impairment 
was 25%, and 36% had difficulties in IADL.  
 
Table 9. Characteristics of the study participants according to sedative load groups in the 
baseline of the GeMS Study  
 
 All  
 
%  (n) 
Sedative 
load 0 
%  (n) 
Sedative 
load 12  
% (n) 
Sedative 
load ≥3 
% (n) 
p-
valuea 
Age     0.004 
 75–79 y 49 (346) 54 (267) 38 (56) 40 (23)  
 80–84 y 31 (215) 29 (142) 35 (51) 38 (22)  
 ≥85 y 20 (139) 17 (86) 27 (40) 22 (13)  
Women 69 (486) 66 (324) 80 (118) 76 (44) 0.002 
Education ≤6 y 51 (346) 50 (240) 50 (72) 63 (34) 0.173 
IADL score ≤6 36 (252) 30 (146) 46 (67) 67 (39) <0.001 
Poor self-rated health 15 (103) 10 (51) 24 (35) 30 (17) <0.001 
Loneliness     <0.001 
 Often 4 (32) 3 (13) 8 (11) 14 (8)  
 Sometimes 32 (225) 28 (138) 41 (60) 47 (27)  
 Never 63 (441) 69 (343) 52 (76) 39 (22)  
Physical activity     <0.001 
 Inactive 36 (245) 31 (150) 44 (62) 60 (33)  
 Moderate or active 64 (429) 69 (328) 56 (79) 40 (22)  
MMSE <25 25 (170) 20 (99) 30 (44) 47 (27) <0.001 
GDS ≥5 8 (55) 5 (25) 12 (18) 21 (12) <0.001 
FCI     0.001 
 0–1 11 (77) 13 (66) 5 (7) 7 (4)  
 2 45 (318) 47 (230) 48 (70) 31 (18)  
 ≥3 44 (305) 40 (199) 48 (70) 62 (36)  
Dementia 16 (109) 12 (61) 20 (30) 31 (18) <0.001 
Unable to walk 
independently 400m 
46 (324) 46 (229) 47 (69) 45 (26) 0.963 
a Categorical variables were tested with chi square test, comparison between sedative load groups 0,  
1–2 and ≥3. 
IADL=Instrumental Activities of Daily Living, MMSE=Mini-Mental State Examination score, 
GDS=Geriatric Depression Scale score, FCI=Functional Comorbidity Index score, y=years 
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Table 10. Characteristics of the study participants according to sedative load groups in the 
baseline of the GeMS Study  
 
 All 
 
Sedative 
load 0 
Sedative 
load 1-2 
Sedative 
load ≥3 
p-
valuea 
 Mean value 
±SD 
Mean value 
±SD 
Mean value 
±SD 
Mean value 
±SD 
 
Mean age 81.3 (4.6) 80.8 (4.4) 82.4 (4.7) 82.5 (5.6) <0.001 
FCI mean 2.6 (1.7) 2.5 (1.7) 2.9 (1.8) 3.4 (1.7) <0.001 
Mean umber of drugs 4.9 (3.2) 4.1 (2.7) 6.4 (3.1) 8.6 (3.6) <0.001 
Mean TUG time, s 13.9 (9.3) 12.5 (8.7) 16.9 (10.2) 17.6 (9.4) <0.001 
Mean walking speed, m/s 1.3 (0.4) 1.3 (0.4) 1.1 (0.4) 1.0 (0.4) <0.001 
Berg Balance Scale, 
mean points 
47.9 (9.1) 49.2 (8.5) 45.1 (9.5) 43.5 (10.9) <0.001 
Mean grip strength, kg 20.0 (10.2) 21.3 (10.4) 17.5 (9.1) 14.9 (8.7) <0.001 
Mean knee extension 
strength, N 
297.6 (110.3) 310.6 (111.5) 257.2 (95.6) 267.2 (104.5) <0.001 
Mean chair stands test 
time, s 
16.7 (7.8) 15.8 (6.6) 19.3 (10.8) 19.6 (7.0) <0.001 
a Continuous variables were tested with analysis of variance, and are presented as means (±SD),  
comparison between sedative load groups 0, 1–2 and ≥3.  
N=Newtons, TUG=Timed Up&Go test, FCI=Functional Comorbidity Index score. 
 
5.1.2 Use of drugs with sedative properties 
Of 700 participants, 29% were users of drugs with sedative properties. Sedative load of 12 
was present in 21% (n=147) of the participants, and 8% (n=58) had a sedative load of ≥3 at 
the baseline of the study.  
Users of drugs with sedative properties were older, more likely to be women, to have 
depressive symptoms, and have cognitive impairment than nonusers of drugs with 
sedative properties (Table 9). They also had higher number of comorbidities, poor self-rated 
health status, and felt themselves more often lonely.  
Mobility and balance test results were poorer among those having a sedative load of 12 
and ≥3 (Table 10). They also had lower muscle strength test results compared to nonusers of 
sedative drugs.  
The most frequently used primary sedatives (group 1) were hypnotics (15%) and 
conventional antipsychotics (3%) (Table 11). SSRIs (5%) and other antidepressants (3%), 
mainly mirtazapine, were most frequently used drugs with sedation as a prominent side 
effect (group 2). Of the participants, 21% used one or more group 1 drugs, and 14% used at 
least one group 2 drug.  
 
 
Table 11. Drug classes contributing to sedative load at the baseline of the GeMS Study. 
Cross-sectional point prevalence of sedative drug use in 2004 (n=700) and in 2007 (n=581) 
 
Drug group Users 2004 
% (n) 
Users 2007 
% (n) 
Change in  
% 
Conventional antipsychotics 3.4 (24) 0.9 (5) -68 
Tricyclic antidepressants 1.7 (12) 1.2 (7) -29 
Anxiolytics 3.3 (23) 3.4 (20) +3 
Hypnotics 14.6 (102) 14.1 (82) -3 
Atypical antipsychotics 2.6 (18) 4.7 (27) +80 
SSRIs 4.6 (32) 4.1 (24) -11 
Other antidepressants 3.4 (24) 6.9 (40) +103 
Antiepileptics 2.1 (15) 2.1 (12) 0 
Opioids 1.9 (13) 3.3 (19) +74 
SSRIs=selective serotonin reuptake inhibitors 
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5.2 FACTORS ASSOCIATED WITH USE OF DRUGS WITH SEDATIVE 
PROPERTIES (I) 
Factors associated with sedative load were investigated in two models; one with regular 
sedative load (only from regularly used drugs) and total sedative load (including regular 
and when-required drugs). In the multivariate analyses, factors associated with a regular 
sedative load of ≥2 were female sex (OR 1.65 [CI 1.022.67]), poor self-rated health (OR 2.06 
[CI 1.253.38], and impaired IADL (OR 1.89 [CI 1.183.01]). Regular sedative load ≥2 was 
also associated with loneliness, and strongest association was found between sedative load 
and often feeling lonely (‘sometimes lonely’ OR 1.77 [CI 1.172.68], ‘often lonely’ OR 4.72 
[CI 2.1510.4]) (Table 12). 
The same factors were significantly associated with having a total sedative load of ≥2 
after inclusion of when-required drugs in the model (Study I).  
 
Table 12. Factors associated with regular sedative load among the GeMS Study participants 
 
 Unadjusted  
OR (95% CI) 
Adjusted  
OR (95%CI) 
Age, years   
 75–79 1.00 1.00 
 80–84 1.60 (1.06–2.42) 1.37 (0.87–2.15) 
 ≥85 2.21 (1.40–3.47) 1.26 (0.74–2.13) 
Gender   
 Male 1.00 1.00 
 Female 1.73 (1.14–2.63) 1.65 (1.02–2.67) 
Alcohol use   
 No 1.00 1.00 
 Yes 0.68 (0.47–0.98) 0.88 (0.59–1.32) 
Self-perceived health   
 Average or good 1.00 1.00 
 Poor 3.02 (1.94–4.70) 2.06 (1.25–3.38) 
IADL   
 7–8 1.00 1.00 
 0–6 2.27 (1.58–3.26) 1.89 (1.18–3.01) 
Dementia   
 Not diagnosed 1.00 1.00 
 Diagnosed 1.80 (1.15–2.82) 1.11 (0.64–1.93) 
Loneliness   
 Never 1.00 1.00 
 Sometimes 2.26 (1.54–3.31) 1.77 (1.17–2.68) 
 Often 6.70 (3.19–14.09) 4.72 (2.15–10.40) 
Cardiovascular disease   
 No 1.00 1.00 
 Yes 1.79 (1.09–2.93) 1.50 (0.87–2.56) 
Factors included in the adjusted analyses were age, gender, alcohol use, self-perceived health, IADL, 
dementia, loneliness and cardiovascular disease. Total number of participants in the models was 674. 
OR=odds ratio, CI=confidence interval, IADL=Instrumental Activities of Daily Living, COPD=chronic 
obstructive pulmonary disease  
 
5.3 PHYSICAL FUNCTION MEASURES ASSOCIATED WITH THE USE (II, 
III) 
5.3.1 Mobility and balance (II) 
Poor performance in all balance and mobility outcomes were significantly associated with 
higher sedative load (p<0.05) in the unadjusted analyses. The unadjusted mean scores for 
walking speed, TUG and BBS were poorer among women than among men (Table 13). In 
the unadjusted logistic regression model, self-reported ability to walk independently 400 m 
was associated with sedative load >0 (OR 2.85 [CI 1.58-5.15]. 
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In the adjusted analyses, participants with a sedative load of >0 had poorer performances 
on walking speed, TUG and Berg Balance scale compared to participants with sedative 
load=0 (Figure 2). None of the outcome measures was able to differentiate between those 
with sedative load of 1-2 and those with sedative load ≥3. After adjusting for covariates, the 
association between sedative load of >0 and self-reported ability to walk independently 400 
meters was no longer significant (OR 1.47 [CI 0.712.06]).  
 
Table 13. Unadjusted outcome means across sedative load groups by gender 
 
Outcomes SL=0 SL=1‒2 SL≥3 p-value 
Walking speed     
     men (n=177) 1.50±0.04 1.28±0.09 1.15±0.14 0.007 
     women (n=396) 1.25±0.02 1.02±0.04 0.93±0.07 <0.0001 
TUG     
     men (n=191) 11.0±0.64 15.8±1.45 15.5±2.36 0.004 
     women (n=438) 13.3±0.55 17.20±0.91 18.20±1.60 0.0001 
Berg balance test     
     men (n=193) 50.20±0.64 45.14±1.50 46.6±2.39 0.005 
     women (n=446) 48.61±0.53 45.04±0.89 42.61±1.50 <0.0001 
Outcomes are presented as mean ± standard error. 
TUG=Timed Up&Go test, SL=sedative load 
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Figure 2. Adjusted means of balance, mobility and muscle strength measures according to 
sedative load groups. Models are adjusted for age, sex, education, cognitive impairment, 
FCI, and physical activity. Error bars represent SE. Parenthesis drawn from sedative load 
(SL)=0 to SL ≥3 represent difference between those two groups 
5.3.2 Muscle strength (III) 
In the unadjusted analyses, grip strength, knee extension strength and chair stands test 
results were associated with sedative load >0 (Table 14).  
Participants with a sedative load >0 had poorer performance in grip strength and chair 
stands test compared to participants with sedative load=0 (p<0.05) in the adjusted analyses 
(Table 14, Figure 2). In the knee extension strength, significant difference was observed 
between people with sedative load of 12 compared to nonusers of drugs with sedative 
properties (p=0.02). In the adjusted analyses, grip strength was the only outcome measure 
that differentiated between those with sedative load of 12 and those with sedative load ≥3 
(p=0.03).  
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Table 14. Unadjusted and adjusted analysis of covariance to compare means of muscle strength 
measures with the exposure to the drugs contributing to sedative load (SL). Means with 95% 
confidence intervals are displayed 
 
Outcomes SL=0 SL= 1‒2 SL≥3 p-value 
Grip strength (kg) 
unadjusted 21.3 (20.4, 22.2) 17.5 (15.9, 19.2) 14.9 (12.2, 17.7) <0.001 
adjusted 20.1 (19.5, 20.8) 19.8 (18.5, 21.0) 17.2 (15.1, 19.3) 0.03 
Knee extension strength (newtons) 
unadjusted 310.6 (300.0, 321.3) 257.2 (236.3, 278.0) 267.2 (229.6, 304.8) <0.001 
adjusted 302.2 (294.1, 310.2) 280.7 (264.9, 296.5) 289.1 (259.6, 318.5) 0.06 
Chair stands test (seconds)* 
unadjusted 14.9 (14.3, 15.3) 17.5 (16.4, 18.7) 16.6 (17.2, 20.7) <0.001 
adjusted 15.2 (14.7, 15.6) 16.8 (15.8, 17.8) 16.9 (15.3, 18.7) 0.003 
*Variable log10 transformed after analysis. 
 
5.4 LONGITUDINAL SEDATIVE LOAD (IV) 
From baseline examination to the final examination in 2007, the sample decreased from 700 
persons to 581 persons (Table 15). The prevalence of sedative drug use increased during the 
study years, from 29% to 36%.  
 
Table 15. Sedative use during years 2004 to 2007 in the GeMS Study population, home-
dwelling (n=700) at the baseline 
 
 2004 
n=700 
2005 
n=656 
2006 
n=621 
2007 
n=581 
 % n % n % n % n 
Nonusers of sedatives 70.7 495 70.0 459 66.3 412 63.9 371 
Users of sedatives 29.3 205 30.0 197 33.7 209 36.1 210 
 1‒2 21.0 147 22.1 145 24.3 151 24.4 142 
 ≥3 8.3 58 7.9 52 9.3 58 11.7 68 
Women using 
sedatives 
33.3 162 33.7 155 37.4 162 38.8 158 
Men using sedatives 20.1 43 21.4 42 25.0 47 29.9 52 
Age groups using 
sedatives 
        
 75‒79 22.8 79 21.6 72 26.5 86 29.7 92 
 80‒84 34.0 73 36.4 72 39.5 73 39.9 69 
 ≥85 38.1 53 42.4 53 44.6 50 50.0 49 
 
 
Drug utilization patterns changed during the follow-up (Table 11). The proportion of 
hypnotic and anxiolytic use remained the same in 2004 and 2007. Conventional 
antipsychotic use decreased from 3% to 1%, and atypical antipsychotic use increased from 
3% to 5%. Use of other second generation antidepressants (mainly mirtazapine) increased 
from 3% to 7%. The proportion of opioid users increased from 2% to 3%. 
The mean sedative load among the study participants increased from 0.67 to 0.83 during 
the follow-up period (Study IV). Women and older age groups used sedative drugs more 
frequently than men or younger age groups (Table 15). The largest increase in the 
proportion of sedative users during the study period was among men (from 20% to 30%) 
and among persons aged 85 years or more (from 38% to 50%).  
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5.5 SEDATIVE LOAD AND MORTALITY (IV) 
There were 159 (22.7%) baseline participants who died prior to December 31, 2008. The 
unadjusted HR for risk of death associated with time-dependent sedative load were 1.40 (CI 
0.98‒2.01) for sedative load 1‒2 and 1.88 (CI 1.20‒2.95) for sedative load ≥3.  
When adjusting for age and gender, sedative load was no longer associated with 
increased mortality (sedative load 1‒2 HR 1.23 [CI 0.87‒1.81], sedative load ≥3 HR 1.53 [CI 
0.96‒2.41]). In the fully adjusted model, sedative load was not associated with risk of death 
(sedative load 1‒2 HR 1.12 [CI 0.76‒1.64], sedative load ≥3 HR 0.92 [CI 0.55‒1.56]) (Table 
16). In this adjusted model, only age and IADL score 0‒6 were associated with a risk of 
death. The main factors that mediated the association between sedative load and death 
were the IADL score, diagnosis of a dementia, and older age.  
 
Table 16. Sedative load and adjusted risk of death 
 
Variable HR 95% CI 
Sedative load, time-dependenta   
 0 ref  
 1‒2 1.12 0.76‒1.64 
 ≥3 0.92 0.55‒1.56 
Age, y   
 75‒79 ref  
 80‒84 1.66 1.10‒2.51 
 ≥85 2.55 1.65‒3.97 
Gender   
 women ref  
 men 1.13 0.78‒1.64 
Education, y   
 >6 ref  
 0‒6 0.93 0.67‒1.30 
IADL score   
 7‒8 ref  
 0‒6 2.01 1.35‒2.98 
FCI   
 0 ref  
 1‒2 0.77 0.42‒1.44 
 ≥3 1.30 0.71‒2.37 
Dementia   
 no ref  
 yes 1.45 0.96‒2.20 
a Time-dependent sedative load, other covariates are measured at the 
baseline.  
FCI= Functional Comorbidity Index, IADL= Instrumental Activities of Daily 
Living, y=years 
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6 Discussion   
6.1 STUDY POPULATION AND DATA COLLECTION 
6.1.1 Study population 
This thesis is based on data collected as part of the GeMS Study which was a randomized 
population-based study. The use of random population-based sample meant that it was 
likely to be representative of the target population. Thus, the results are likely to be 
generalizable to older people in the municipality of Kuopio, Finland. The results are also 
likely to have a high degree of generalizability to older people in Finland because of drug 
reimbursement system that is the same for all people across the country (Bell et al. 2007, 
Furu et al. 2010). In addition, Finland is ethnically homogenous and health care provided 
by municipalities is organized according to a national framework (Ministry of Social Affairs 
and Health 2008). The study may have limited generalizability to countries with different 
patterns of prescribing and primary health care systems.  
The response rate (78%) in the GeMS Study can be considered good. Analyses also 
suggested that the characteristics of participants and non-participants were similar. For 
those persons who refused or were unable to participate to the study, the mean age and 
gender distribution matched well with participants. These factors support the 
generalizability of the results. In clinical studies, response rates over 70% are traditionally 
considered good (Jesson 2001).  
In the thesis, persons living in institutional care were excluded. The main reasons were 
that persons in institutional care typically have higher exposure to drugs with sedative 
properties, different determinants of drug use, and different predictors of functional 
disability compared to those living in community-based settings (Rigler et al. 2004, Van 
Rensbergen & Nawrot 2010, Haasum et al. 2012).  
6.1.2 Study protocol 
Studies IIII were cross-sectional whereas Study IV was longitudinal. Cross-sectional data 
do not allow determination of causality. The results of the cross-sectional studies should be 
interpreted cautiously. Drugs with sedative properties may have been selectively 
prescribed to participants at higher risk of impaired balance, mobility and muscle strength. 
Adjustments were made for confounders that were considered clinically important but the 
possibility of residual confounding cannot be excluded 
The study protocol was based on interviews conducted by three trained nurses. It was 
designed to assess drugs that participants were actually using rather than drugs intended 
for use. The use of nurse interviews to assess drug use, therefore, represented an advantage 
over the use of prescribing or dispensing records (Lau et al. 1997, Rikala et al. 2010). During 
the interview, medical records of each participant were available to study nurse and drug 
use recorded in the medical record but not self-reported by the participant was specifically 
enquired about. Recall bias was minimized by asking participants to take drug packages 
and prescription forms to the interview. In the interview, it was also possible to distinguish 
between drugs that were taken regularly and drugs that were taken on when-required 
basis. This was especially important in case of psychotropic drugs which are often 
prescribed on when-required basis but may actually be used regularly (Baker and Oleen 
1988). However, if a participant was unwilling to report use of a drug and it was prescribed 
by a private practitioner, it was not possible to determine its use.  
The GeMS Study was a randomized comparative study and included an intervention, 
namely Comprehensive Geriatric Assessment. The intervention included an examination 
by two physicians who were trainees in geriatrics, and thus, there may be some differences 
49 
 
 
between intervention and comparison groups in terms of diagnosed diseases. This was 
because physicians referred participants randomized to the intervention group to special 
health care if they identified a need for this. In addition, study nurses acted as case 
managers for participants and their families in the intervention group, and provided 
counseling and support. However, regardless of their study group allocation, all 
participants continued to receive standard care during the GeMS Study. Although one aim 
of the medication assessment was to review psychotropic drug use the intervention did not 
have effect on the utilization of psychotropic drugs (Rikala et al. 2011). The intervention 
was effective in terms of optimizing physical function (Lihavainen et al. 2011) but only 
baseline data were used in Studies II and III in this thesis. These data were collected before 
the intervention began. The interventions targeted at improving physical function and 
reducing inappropriate drug use could have potentially impacted mortality of the 
intervention group. However, mortality between the groups was found to be similar. This 
may have been because the annual examination of the comparison group also served as a 
form of intervention. If the need for immediate care was identified during the annual 
examinations, then a participant in the comparison group was guided to appropriate health 
services.  
6.2 SEDATIVE LOAD MODEL 
The Sedative Load Model is a comprehensive and previously published classification of 
drugs with sedative properties (Linjakumpu et al. 2003, Linjakumpu et al. 2004). The model 
was developed in Finland, and before Study I, it was updated with drugs that came onto 
the market after the publication of the original model. These updates were published in 
Study I of this thesis. Thus, the model can be considered comprehensive in terms of the 
drugs used by the GeMS Study participants. Furthermore, the model took into account the 
use of multiple drugs with sedative properties. This was important because in ‘real-life’ 
settings older people often use multiple drugs with sedative properties (Linjakumpu et al. 
2004, Jyrkkä et al. 2006, Hilmer et al. 2007, Hanlon et al. 2009)  
Compared to other metrics that measure the cumulative effect of taking multiple drugs 
with sedative properties, the Sedative Load Model is most comprehensive in terms of the 
drugs and drug classes that are included (Taipale et al. 2010, Table 1). The Sedative Load 
Model also includes drugs for somatic disorders. Besides the drug classes considered, the 
cumulative methods differ in terms of sedative ratings assigned to each drug, the inclusion 
or exclusion of drug dose in the model and each model’s likely ease of use in clinical 
practice. In these models, sedative ratings are assigned by consensus, and were not 
previously validated which is a limitation of the Sedative Load Model.  
One possible limitation of the model is that it does not include doses of drugs. The 
presence of dose-response relationship is commonly regarded as evidence for causality of 
an ADR (Naranjo et al. 1981). However, there is a lack of evidence from clinical trials to 
inform appropriate drug dosing in people aged 75 years and older including sedative drugs 
(Hilmer et al. 2011). Thus, choosing “reference doses” for metrics that assess the cumulative 
effect of drug burden is problematic. Furthermore, different indications may be treated 
with different doses of a drug, and this is a difficult factor to incorporate into the metrics.  
Interestingly, a study utilizing the Drug Burden Index found similar associations with 
impairments in physical function as was found with sedative load among the GeMS Study 
participants (Gnjidic et al. 2011). The Drug Burden Index also includes doses of drugs. It is 
not known to what extent the similarities in findings between DBI and sedative load extend 
to other study samples.  
In this thesis, when-required drugs were not considered when calculating sedative load 
in Studies IIIV. In Study I, factors associated with the use of drugs with sedative 
properties did not change when including when-required drugs in the analyses. Similarly, 
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in the development of DBI the inclusion of when-required drugs in the analyses had only 
minimal effect on the associations between DBI and physical and cognitive function, and 
thus, DBI does not consider when-required drugs (Hilmer et al. 2007). In the GeMS Study, 
the specific frequency of when-required drug use was not known, or it was less than four 
times a week. Thus, inclusion of when-required drugs might have produced an 
overestimation of sedative effects of drugs and associations towards the null. For these 
reasons, when-required drugs were not considered in Studies IIIV. As a consequence, 
sedative loads reported in the thesis may be underestimation of total drug use.   
In this thesis, sedation is defined as subjective feelings of drowsiness and sleepiness, and 
decreased psychomotor functioning. Psychomotor functioning includes speed of processing 
in the CNS, and also aspects of attention and memory. These are also related to each other, 
because poor attention decreases speed of processing or increases mistakes. SSRIs are often 
considered as non-sedating, but they have been shown to impair cognitive and 
psychomotor processing although to a lesser extent than benzodiazepines (Hindmarch 
2009). In addition, Hindmarch analyzed cognitive toxicity of different psychotropic drugs, 
and found that SSRIs possessed the largest intraclass variation.  
The Sedative Load Model does not include past use of sedative drugs. This may be a 
limitation although the importance of past use of sedative drugs on physical function has 
not been widely studied. In a study by Gray and coworkers, long-term benzodiazepine use 
was associated with decline in physical function but past use was not (Gray et al. 2003). 
Impaired cognition associated with benzodiazepines has been shown to resolve after 
withdrawal of these drugs but some impairments remain in comparison to never-users 
(Barker et al. 2004). Past use of sedative drugs might have an impact on physical function 
decline if sedative drug use caused physical inactivity. Physical inactivity has been 
associated with decreased muscle strength (Rantanen et al. 1999, Goodpaster et al. 2008).  It 
is possible to regain muscle strength but it requires regular muscle strength training or 
other physical activity. Thus, without an increase in physical activity after ceasing sedative 
drugs, the impairments in muscle strength may persist. In the GeMS Study, there were no 
data on duration of drug use or past use of drugs at the baseline.  
Study IV included prevalent users of sedative drugs without knowledge of the duration 
of drug use. This introduces the possibility that the study sample comprised a group of 
survivors. If these drugs would have an impact on mortality at the start of the treatment, 
then this study design may not reveal an increased risk of death. However, there are also 
problems in alternative data sources, i.e. prescription registers, in terms of classification of 
exposure to sedative drugs. Using prescription registers, incident use could be determined 
according to the day that a drug was first dispensed. However, this could lead to 
misclassification because use of the drug may not have been started at that day, or started 
at all (Pit et al. 2008, Noize et al. 2009). Prescription registers do not include data on non-
adherence to drug use. Furthermore, prescription registers typically include limited data on 
comorbidities that analyses regarding mortality hazard should be adjusted for (Furu et al. 
2010). Interview data verified from medical records has an advantage over prescription 
registers due to knowledge about which drugs are actually used and which diagnosed 
diseases participants actually have. In addition, in the GeMS Study the group of sedative 
never-users decreased during the study period which indicates that all users were not long-
term users.  
One limitation of the Sedative Load Model is that drug groups included and rated with 
sedative rating have intraclass variation in regard to sedative potential. Intraclass variation 
of SSRIs was discussed above, but there is also variation in sedative potential of 
conventional and atypical antipsychotics. In future studies, the possibility to define 
subgroups within the major drug groups should be considered. Another possibility could 
be to use a measure to rate individual drugs based on their sedative potential. This could be 
done utilizing proportional impairment ratios (PIRs) to summarize data from placebo-
controlled psychometric tests with several aspects of cognitive and psychomotor function 
51 
 
 
(Hindmarch 2009). The PIR method has been used to rate sedative potential and cognitive 
toxicity of psychotropic drugs and antihistamines among healthy young volunteers 
(McDonald et al. 2008, Hindmarch 2009). It would be worth studying the correlation 
between impairment ratios in younger and older people. Furthermore, the impact of 
comorbidities on sedative potential could be investigated. One future objective could be to 
investigate does subjective or objective sedation test results correlate with sedative load of a 
participant.  
6.3 DEFINITIONS AND MEASUREMENTS 
6.3.1 Comorbidities and mortality 
Participant self-reported diagnoses were complemented with data obtained from the 
Finnish National Prescription and Special Reimbursement Registers maintained by the 
Social Insurance Institution of Finland (SII) (Furu et al. 2010). The Finnish Prescription 
Register is a nationwide claims database which includes information on all reimbursed 
drug purchases in Finnish community pharmacies. The Special Reimbursement Register 
includes people who are entitled to receive reimbursements above the basic refund level. 
Receiving a higher level of refund is based on diagnoses and a certificate from a physician 
fulfilling explicit criteria established by the SII. In the GeMS Study, medical records were 
present at the nurse interview, physiotherapist interview, and examination by physician. By 
combining these data sources  it was ensured that diagnostic data were complete. 
To adjust for comorbid diseases in Studies II‒IV, the Functional Comorbidity Index was 
utilized (Groll et al. 2005). The FCI is a previously validated index that takes into account 
medical conditions that have been shown to predict physical function in older persons. 
However, other comorbidities not included in the FCI and undiagnosed diseases may also 
have impacted the association between sedative load and physical function. In Study IV, 
other diseases affecting mortality were considered. As a result, dementia was included in 
the Cox proportional hazards models but there were a too small number of cases with 
active cancer to be included in the analysis. One limitation with the FCI is that it does not 
take into account disease severity which may also affect the associations. Thus, 
confounding by indication cannot be ruled out.  
6.3.2 Physical function measures 
Physical function tests were conducted by one of two trained physiotherapists. Balance and 
mobility tests included walking speed, TUG and Berg Balance scale which have been 
previously utilized and validated among older people (Podsiadlo et al. 1991, Berg et al. 
1992, Montero-Odasso et al. 2005). Measurements were performed in standardized 
circumstances, and by two trained physiotherapists who encouraged participants to do 
their best in the tests.  
The participation rate in balance, mobility and muscle strength tests varied from 75% to 
90%. When considering persons aged 75 years and older, these participation rates can be 
considered good. Reasons for nonparticipation in physical function testing were mainly 
related to difficulties in mobility and transporting to health centre to attend the testing. 
Most of the performance-based tests (walking speed, TUG, BBS and knee extension 
strength) could not be performed in the participant’s home.  
Muscle strength tests utilized in Study III were grip strength, knee extension strength 
and chair stands test which also includes aspects of mobility and balance. Of these tests, 
grip strength is the most widely used muscle strength tests among older people, and it has 
been shown to predict numerous functional outcomes, including an increased risk of 
fractures and cognitive decline (Cooper et al. 2011). Knee extension strength and chair 
stands test both describe function of lower extremities which is important in mobility and 
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balance, and in active independent living. In addition, muscle strength tests were 
conducted by two trained physiotherapists which is strength of the study.  
6.4 DISCUSSION OF THE RESULTS 
6.4.1 Prevalence of use of drugs with sedative properties (I) 
At the baseline of the GeMS Study, 29% of the participants used one or more drugs with 
sedative properties. When considering when-required drugs, the prevalence was 45%. In a 
study by Linjakumpu and coworkers in 19981999, 40% of community-dwelling older 
people aged ≥64 years used ≥1 drugs with sedative properties (Linjakumpu et al. 2004). In 
that study, when-required drug use was also included and thus, prevalence is comparable 
to Study I. There are no other studies of sedative load conducted among community-
dwelling persons to compare these current results. 
Studies among older people living in residential aged care and long-term care facilities 
have reported higher prevalences of sedative drug use compared the GeMS Study (Taipale 
et al. 2009, Parsons et al. 2011). In Northern Ireland, the prevalence of sedative drug use 
was 67% among persons with dementia (Parsons et al. 2011). In Finland, 85% of residents of 
long-term care facilities in Helsinki were reported to use at least one drug with sedative 
properties (Taipale et al. 2009). It is somewhat controversial because often the frailest older 
people live in the care facilities. There may also be differences between countries and 
treatment cultures but the lack of studies prevents international comparison.  
The prevalence of sedative drug use measured with other methods to quantify 
cumulative exposure to drugs with sedative properties has reported lower utilization rates 
among community-dwelling older people. The prevalence of the sedative component of the 
DBI was 1316% of community-dwelling participants (Table 2). Sedative drug use 
according to CNS drug model was 14% of the participants. The differences may be 
explained by fewer drug classes included in these models. However, the prevalence of 
sedative drug use in the GeMS Study is higher compared to studies with DBI and CNS 
drug model because the prevalence of hypnotic users was 15%. Psychotropic drug use has 
been reported to be higher in Finland compared to other Nordic countries among 
community-dwelling persons (Linjakumpu et al. 2002). 
The most frequently used drugs with sedative properties were hypnotics. These were 
used by 15% of the participants were using. This was a similar prevalence to that reported 
by Linjakumpu et al. (Linjakumpu et al. 2002) although in Linjakumpu’s study when-
required drug use was also included. Use of hypnotics among community-dwelling Finns 
did not decrease between the studies in 1998-99 (Linjakumpu et al. 2002) and 2004 (Study I).  
The prevalence of anxiolytic use was 3% at the baseline of the GeMS Study whereas it 
was reported to be 10% among community-dwelling participants in Lieto in 199899 
including when-required drug use (Linjakumpu et al. 2002). The difference may be related 
to decreased use of anxiolytics among community-dwelling older people or variations in 
local treatment cultures (Lieto compared to Kuopio). However, the difference is most likely 
explained by the inclusion of when-required anxiolytic use in the study by Linjakumpu et 
al. because anxiolytics are often used on when-required basis rather than regularly. In long-
term care facilities anxiolytics were the most prevalent sedative drug class in 2003 (Taipale 
et al. 2009), whereas hypnotics were the most common drugs among community-dwelling 
samples (Study I, Linjakumpu et al. 2002).  
Factors associated with sedative load in the multivariate analyses included female 
gender. Linjakumpu et al. reported a similar finding in their study. This may reflect gender 
differences in healthcare utilization behavior and prescribing patterns which has been 
reported for psychotropic drug use (Gleason et al. 1998, Voyer et al. 2004). However, 
sedative load was not associated with age in the adjusted model which is in contrast to the 
previous study by Linjakumpu et al. In the adjusted model, IADL and gender had the most 
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prominent impact on the association between sedative load and age. This provides an 
explanation for the lack of association between sedative load and age. 
Impaired IADL was associated with use of drugs with sedative properties. Linjakumpu 
et al. did not measure IADL in their study but they reported that sedative load was 
associated with difficulties or dependence in mobility (Linjakumpu et al. 2004). The 
association between IADL and sedative load could reflect acute sedation experienced by the 
participants which infers their attention, psychomotor function and reaction time which are 
important in complex tasks of daily living like shopping and taking care of financial issues. 
However, it is also possible that the association reflects drug channeling bias. 
Loneliness was strongly associated with sedative load in Study I. Loneliness may be 
associated with depressive symptoms, and in the previous study of sedative load, the 
association between sedative load and depressive symptoms was reported (Linjakumpu et 
al. 2004). In both Study I and in Linjakumpu’s study, loneliness and depressive symptoms 
were variables with the highest adjusted odds ratios in the multivariate models. Use of 
benzodiazepines and also other psychotropic drugs have been associated with depressive 
symptoms in several studies (Dealberto et al. 1997, Blazer et al. 2000, Carrasco-Garrido et al. 
2007). Benzodiazepine use has also been reported to be a marker of untreated depression 
(Assem-Hilger et al. 2009). The subjective feeling of loneliness may also directly influence 
on use of drugs with sedative properties. Loneliness may reflect social isolation and these 
drugs may be used to escape these feelings. It is notable that in this study, loneliness was 
assessed as a subjective feeling of being lonely and it was strongly associated with sedative 
load. However, living alone was not associated with sedative load. Previous studies that 
have investigated the association between loneliness and psychotropic drug use have been 
inconclusive, although this may be partly due to the difficulty of operationalizing the 
concept of loneliness (Voyer et al. 2004).  
Poor self-rated health was associated with sedative load in Study I. This finding was 
consistent with the previous study by Linjakumpu et al. The relationship may be 
multidimensional; the poor perceptions of health may negatively impact mental health 
leading older people to seek help for sleep problems and psychological symptoms. 
Alternatively, drugs with sedative properties may lower mood and physical performance, 
and lead to poorer perceptions of health (Voyer et al. 2004). Participants’ self-rated health 
may also accurately reflect actual health status, and describe the increasing number of 
comorbidities which are treated with an increasing number of sedative drugs. 
6.4.2 Association between sedative load and physical function (II, III) 
In Studies II and III, sedative load was found to be associated with poorer performance in 
balance, mobility and muscle strength tests. Various aspects of physical function were 
measured and all showed impairments in performance among users of sedative drugs.  
Sedative load and physical function has not been studied before and thus, Studies II and 
III in thesis are the first studies to report this association. Declines in physical function have 
been reported with sedative drug use measured with other cumulative exposure methods 
(Table 4). The Drug Burden Index has been associated with declines in physical function 
measured with grip strength, chair stands, walking speed, self-reported physical function 
measures, TUG and Berg Balance scale. DBI has also been investigated among the GeMS 
Study participants and similar impairments were reported in physical function measures 
compared to the results of Studies II and III (Gnjidic et al. 2011a). Although DBI also 
includes anticholinergic drugs without sedative properties, sedative load and DBI were 
associated with similar impairments in physical function. Thus, these indices may be useful 
in indicating inappropriate drug use patterns which are associated with impairments in 
clinically important physical function.  
In contrast, the CNS drug model has not been studied with performance based physical 
function measures. Use of sedative drugs according to CNS drug model has been 
associated with an increased risk of falls (Hanlon et al. 2009). DBI have been investigated in 
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relation to risk of falls only in one study among older people living in residential aged care 
facilities (Wilson et al. 2011). Falls are an important future outcome for research also among 
community-dwelling older people. Falls are particularly dangerous among older people 
because of the risk of fractures. Drug classes included in the sedative load have been 
associated with an increased risk of falls (Hartikainen et al. 2007) and thus, it could be 
expected that cumulative exposure to sedative drugs would be associated with an increased 
risk of falls. 
Previous studies of drug classes contributing to sedative load and impaired physical 
function support findings of Studies II and III. Benzodiazepines are the most frequently 
studied drug group, and have been associated with impairments in ADLs and IADLs in 
several studies (Ried et al. 1998, Ebly et al. 1997, Gray et al. 2006, Landi et al. 2007). 
Benzodiazepine use has been associated with self-reported mobility difficulty, (Gray et al. 
2006), lower scores on short physical performance battery (Landi et al. 2007), and decreased 
walking speed (Eto et al. 1998). Use of antipsychotics and opioids has also been associated 
with impairments in ADL functions (Lord et al. 1995, Ebly et al. 1997). However, there is a 
lack of studies concerning use of sedative drugs and performance-based physical function 
tests. Measuring drug use with indices of cumulative exposure to sedative drugs offers an 
advantage over studies of single drug classes. Older people often use multiple drugs with 
sedative properties which may impact with associations studied with a single drug class or 
lead to exclusion of persons using multiple drugs with sedative properties.  
Impairments in muscle strength have been reported in users of benzodiazepines and 
other psychotropic drugs. Diazepam has been shown to delay activation of muscles 
(Cutson et al. 1997), and use of psychotropic drugs has been associated with decreased 
quadriceps and ankle muscle strength (Lord et al. 1995). Benzodiazepine use has been 
associated with poorer balance measures among older people (Lord et al. 1995) although 
benzodiazepines have been shown to impair balance and postural sway among healthy 
volunteers (McClelland 1989). Thus, it can be concluded that results of Studies II and III are 
consistent with the results of the previous studies. 
Although previous studies support the association between sedative drug use and 
impaired physical function, Studies II and III utilized cross-sectional data, and causal 
relationship cannot be concluded. DBI and physical function has also been studied in 
longitudinal studies (Hilmer et al. 2009, Wilson et al. 2010), as well as CNS drug use and 
falls and mobility limitation (Hanlon et al. 2009, Boudreau et al. 2009). It cannot be ruled 
out that the associations between physical function measures and sedative load were 
caused by residual confounding by indication. Unmeasured comorbidities or varying 
severity of diseases could have caused the associations. Sedative load and physical function 
measures should be studied in longitudinal design to be able to determine if changes in 
physical function are more pronounced among sedative drug users compared to nonusers. 
Another possibility is to investigate physical function among incident users of sedative 
drugs before and after the start of the treatment.  
Physical function tests utilized in Studies II and III have been widely used among older 
people and these tests are shown to predict important outcomes. Slower walking speed has 
been associated with hospitalizations (Cesari et al. 2005, Montero-Odasso et al. 2005). Poor 
performance in various tests including walking speed, TUG, Berg Balance scale, grip 
strength and knee extension strength has been associated with an increased risk of falling 
(Shumway-Cook et al. 2000, Lajoie et al. 2002, Montero-Odasso et al. 2005, Morris et al. 
2007, Pijnappels et al. 2008). Weaker grip has also been associated with an increased risk of 
fractures (Cooper et al. 2010). Most of these tests are also predictors of mortality. Poor 
performance in walking speed, grip strength, knee extension strength and chair stands test 
have been associated with an increased risk of death (Rantanen et al. 2003, Newman et al. 
2006, Morris et al. 2007, Cesari et al. 2009). Physical functioning is also important for active 
and independent living in older people. Decline in muscle strength typically occurs first, 
followed by impairments in mobility because muscle strength is crucial for mobility 
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functions (Rantanen et al. 1999). Declines in muscle strength are hazardous for independent 
living, for example weakness in lower extremities may result in inability to rise from a 
chair, or lifting up an object from the floor. Independent living is very challenging and 
requires intensive help from home-nursing services if muscle strength of lower extremities 
limits these functions. 
Differences in physical function test results between users and nonusers of sedative 
drugs in Studies II and III were clinically relevant. The mean difference in adjusted walking 
speed between those with SL=0 and SL≥3 was 0.2 m/s which is considered clinically 
relevant (Gill 2010). In Study II, the time taken to complete the TUG test was 15.2 seconds 
for those with SL≥3 compared to 13.3 seconds for those with SL=0. This is clinically 
important as older adults who take longer than 14.0 seconds to complete the TUG have 
been shown to be at higher risk of falling (Shumway-Cook et al. 2000). Clinically relevant 
change was also observed in grip strength in Study III. Compared to nonusers of sedatives, 
those with sedative load ≥3 had 2.9 kg lower grip strength after adjustments for covariates 
(20.1 kg vs. 17.2 kg). In a previous study, it was demonstrated that a 2.0 kg decline in grip 
strength among men and women aged 5973 years was equivalent to five years of 
chronological ageing (Ashfield et al. 2010). In Study III, participants with a sedative load >0 
took more than 17.1 seconds to perform five chair stands. Previous studies have 
demonstrated that this length of time was predictive of adverse outcomes (Cesari et al. 
2009). In a study conducted by Cesari et al., older people who took ≥17.1 seconds to 
complete five chair stands were at higher risk of developing persistent severe lower 
extremity limitation, and a higher risk of death during follow-up.  
The pharmacological mechanisms behind the association between sedative drug use and 
impaired physical function are not clear. It is likely that mechanisms leading to mobility 
limitation are multidimensional, and may be due to drug related cognitive impairment, 
impaired psychomotor performance, overall sedation, slowing of neuromuscular 
processing in the CNS, and muscle-relaxants effects and reduced muscle function (Davidoff 
1985, Cutson et al. 1997, Young-McCaughan et al. 2001, Buffett-Jerrott et al. 2002, Turner et 
al. 2006, Wezenberg et al. 2007, Hindmarch 2009). Psychomotor slowing, as indicated by 
prolonged reaction times, delays in muscle activation and impaired attention, is likely to be 
the main factor behind the association between use of sedative drugs and impaired physical 
function. All sedative drug classes have the potential to cause psychomotor slowing 
(Hindmarch 1980). Sedative drugs also have muscle-relaxant properties due to various 
pharmacological mechanisms (Davidoff 1985). However, it is notable that muscle-relaxant 
effects of benzodiazepines occur at higher doses than the anxiolytic effects based on 
required receptor occupancies (Möhler et al. 2002), although the clinical relevance of the 
difference has not been studied among older users. In addition, aging has been associated 
with changes in GABA-A receptors and their subtypes (Turnheim 2003) and thus, muscle-
relaxant effects of benzodiazepines are not fully known among older people.  
In addition to these direct drug-related mechanisms, the association between sedative 
drug use and impairments in physical function may be related to physical inactivity, and 
thus, disuse atrophy caused by decrease in physical activity. Another possibility is that 
sedative drugs are more often prescribed to persons with impairments in physical function. 
Sedatives are often prescribed to persons with cognitive impairment, and cognitive 
impairment has been associated with impaired muscle strength (Atkinson et al. 2010). 
However, the analyses in Studies II and III were adjusted for physical activity level and 
cognitive impairment. 
In Studies II and III, there was a lack of dose-response relationship between increasing 
sedative load and performance in physical function tests. The presence of a dose-response 
relationship is considered indicative of causality for ADRs (Naranjo 1981). Among the 
GeMS Study participants, there was relatively small sample size of participants with a 
sedative load of ≥3 (n=58), and all of them did not participate in the physical function 
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testing. Thus, the possible dose-response relationship between sedative load and physical 
function tests requires further investigation in studies with larger sample sizes. 
6.4.3 Longitudinal sedative load (IV) 
One of the main findings of the Study IV was that the prevalence of any regular sedative 
drug use increased during the 3-year follow-up. This reflects the tendency to initiate 
sedative drug use with increasing age. The proportion of all user categories (i.e. those with 
sedative load of 12 and those with ≥3) increased whereas proportion of nonusers 
decreased.  
The proportion of those with sedative load of ≥1 increased from 29% in 2004 to 36% in 
2007. There are few previous longitudinal studies of sedative or psychotropic drug use 
among the same community-dwelling older people. In a study by Hanlon et al., use of CNS 
drugs (i.e. antipsychotics, antidepressants, benzodiazepines, and opioids) increased during 
a 5 year follow-up period (Hanlon et al. 2009). The proportion of those using one or more of 
these drugs increased from 14% to 18%. In the Kuopio 75+ Study, the prevalence of 
psycholeptic use (i.e. antipsychotics, anxiolytics and sedative-hypnotics) increased from 
31% in 1998 to 43% in 2003 among persons aged 75 years or older and living in community 
at the baseline (Jyrkkä et al. 2006). The higher prevalence compared to the current study 
may partly be explained by inclusion of when-required drug use in the analyses. 
During the follow-up, changes in drug classes contributing to sedative load occurred. In 
2007, atypical antipsychotic use (5%) was more prevalent than conventional antipsychotic 
use (1%) whereas in 2004, the opposite was found. Among antidepressants, other second 
generation antidepressants were the most frequently used antidepressants in 2007 whereas 
in 2004, SSRIs were the most frequently used. The most common drug in the class of other 
antidepressants was mirtazapine which may also be used to treat insomnia.  
The prevalence of sedative drug use increased with age, and increased within age 
groups during the follow-up. There was a marked increase in sedative drug use among 
those aged ≥85 years; from 38% in 2004 to 50% in 2007. This means that in 2007, half of all 
persons aged 88 years or older used drugs with sedative properties. A notable increase in 
the prevalence of sedative drug use was seen among men, from 20% to 30% during the 3-
year follow-up period. 
6.4.4 Association between sedative load and mortality (IV) 
Sedative load was associated with an increased risk of death in the unadjusted analyses, but 
the association was no longer significant after adjusting for covariates. These results were 
consistent with a previous study of long-term care facility residents that found no 
association between baseline sedative load and mortality (Taipale et al. 2009). Similar 
results have been reported with Drug Burden Index. The DBI was not associated with in- 
hospital mortality among older hospitalized patients in the United Kingdom (UK) (Lowry 
et al. 2011), and among older people in residential aged care facilities in Australia (Wilson 
et al. 2012). The results of Study IV suggest that impaired cognition and IADL have a 
greater impact on mortality than use of drugs with sedative properties. However, cognitive 
impairment may increase the susceptibility to ADEs associated with sedative drugs. In 
addition, in Study I, an association between sedative load and impaired in IADL was 
identified.  
The cumulative exposure to sedative drugs has been associated with impaired physical 
function. However, Study IV and above mentioned three studies with sedative load and 
DBI have concluded that there is no association between sedative drug use and mortality. 
This implies that these cumulative exposure measures are more predictive of functional 
abilities than mortality. However, it is possible that study samples (from 362 to 1004) have 
been under powered in the mortality studies because older people have various competing 
causes of death.  
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In previous studies, antipsychotic use has been associated with an increased risk of death 
whereas studies on benzodiazepines have reported conflicting results (Kripke et al. 2012). 
The majority of sedative load in the GeMS Study sample consisted of hypnotic and 
anxiolytic use (55%) and antipsychotic use was not common. Our results may reflect the 
differential risk of death associated with different drug groups. Solomon and coworkers 
found that opioid users had an increased risk of death compared to NSAID users (Solomon 
et al. 2011a). They also found that opioid use was associated with an elevated risk of falls 
and fractures. However, in the GeMS Study the proportion of opioid users was low 
throughout the follow-up period.  
Studies regarding use of antidepressants and mortality have identified both an increased 
and decreased risk of death (Coupland et al. 2011, Ried et al. 2011). These discrepancies 
may reflect differences in patient populations. Coupland and coworkers analyzed persons 
diagnosed with depression whereas Ried et al. studied patients who had suffered a stroke. 
Antidepressants are prescribed for a variety of indications, including depression, anxiety 
and neuropathic pain, and observational studies of antidepressant use may be subject to 
confounding by indication. Similarly, antidepressant use is itself a risk factor for stroke and 
it is difficult to assess if increased risk of stroke is caused by antidepressant use or 
underlying depression (Smoller 2011).  
In Study IV, time-dependent sedative load was utilized to take into account the changes 
in sedative drug use during follow-up period. Previous studies have utilized cross-sectional 
assessments of drug use at the baseline only (Merlo et al. 2000, Taipale et al. 2009, Gisev et 
al. 2011, Lowry et al. 2011). In Study IV, the mean sedative load of baseline sedative users 
decreased while the mean sedative load of baseline nonusers increased. This indicates that 
baseline users decreased or ceased use of sedative drugs and new users started drug use. In 
the GeMS Study, drug use was reassessed at yearly intervals and thus, the actual timing of 
starting or stopping drugs was not known. This may partly explain the negative result 
because previous studies on antipsychotics and opioids have concluded that the risk of 
death is greatest at the start of treatment (Wang et al. 2005, Solomon et al. 2010b).  
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7 Conclusions 
This thesis investigated the association between sedative load and adverse drug events 
among community-dwelling people aged 75 years and older. Conclusions based on the four 
studies included in the thesis are as follows: 
 
1. Nearly every third older person had a sedative load ≥1 when only regularly used drugs 
were considered. Sociodemographic and health-related factors associated with having a 
higher sedative load were female sex, poor self-rated health and impaired IADL. The 
strongest association was found between sedative load and subjective feelings of loneliness.  
 
2. Sedative load was associated with impaired balance and mobility among community-
dwelling older people. Although causality cannot be inferred from results of cross-sectional 
studies, the findings suggest that clinicians should pay special attention to the possibility of 
impaired physical function associated with the use of multiple sedative drugs. 
 
3. Sedative load was associated with impaired muscle strength, and higher sedative load 
was associated with poorer grip strength. This is important because maintenance of 
adequate muscle strength is a crucial factor enabling independence and living at home for 
older people. 
 
4. The prevalence of sedative load increased during the 3-year follow-up. At the end of 
study, 36% of participants used sedative drugs, and half of persons aged 88 years and older 
used one or more sedative drugs. Sedative load was not associated with an increased risk of 
death. Frequent and increasing use of sedative drugs with increasing age highlights the 
importance of developing strategies to optimize and rationalize use of these drugs among 
older people. 
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8 Implications for the future 
Implications for practice 
 
1. Clinicians should pay special attention to the frequent use of sedative drugs. Older 
persons may also seek or be prescribed sedative drugs for unapproved indications for 
which social interventions should be recommended. When prescribing, dispensing or 
administering sedative drugs, clinicians should monitor treatment and ADEs, ensure 
appropriate indication, and prevent intermittent and short-term treatments from evolving 
into regular and long-term use.  
 
2. The association between sedative load and impaired physical function provides 
additional evidence that sedative load may have serious consequences for older people. 
Clinicians should monitor ADEs and changes in physical function when re-assessing 
sedative drug use. The maintenance of adequate muscle strength and mobility is important 
for independence of older people.  
 
3. High sedative load can be considered as a risk indicator that a person may have or be at 
risk of having impaired physical function. Thus, the Sedative Load Model could be utilized 
to identify older persons who are in need for interventions such as medication assessment, 
withdrawal of sedative drugs and improvement of physical function. 
 
4. Older people who are using sedative drugs may not attribute the ADEs they experience 
to their drug therapy. Information and education of patients and family members about 
ADEs should be considered to be able to impact on prevalence of sedative drug use. In 
addition, all sedative users should receive advice and support to gradually reduce their use 
of sedative drugs. 
 
5. The societal impact of frequent sedative drug use and corresponding ADEs should be 
considered in terms of current healthcare systems and policy to support independent living 
of older people. The current objective is to maintain physical function and independence 
and thus, sedative drug use should be recognized as one important factor that may 
counteract these objectives. There is a need for regular assessment of drugs used by older 
people and this should be done systematically and annually with special focus on ADEs. 
There is also a need for evidence-based treatment guidelines for older people. 
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Implications for research 
 
1. The prevalence of sedative load should be assessed in different patient populations and 
countries with different healthcare systems and prescribing practices. Longitudinal studies 
are needed to assess how different drugs contribute to increasing sedative load, and if 
similar factors are associated with the use.  
 
2. The association between sedative load and impaired physical function should be further 
investigated. Prospective, longitudinal studies should be conducted to observe if functional 
decline is more severe among sedative users compared to nonusers. In addition, it is also 
important to assess if the association is caused by the direct effects of sedative drugs on 
muscles or slowing of processing information in the CNS, or indirect effects in terms of 
decreased physical activity and disuse atrophy. 
 
3. The predictive validity of the Sedative Load Model with regard to being able to predict 
declines in physical function should be assessed. In addition, the Sedative Load Model 
should be further updated to include new drugs. Further evidence is needed to inform the 
allocation of sedative ratings to specific drugs.   
 
4. One future objective is to conduct further studies to assess the possible association 
between sedative load and mortality. While antipsychotic use has been associated with an 
increased risk of death in various studies, findings in relation to the risk of death associated 
with other sedative drugs are mixed. For mortality studies, larger samples of older people 
are needed. Where possible, future studies should utilize incident use cohorts of sedative 
users rather than prevalent use cohorts to overcome possible survivor bias. 
 
5. Further studies are also needed to assess the possible association between sedative load 
and a range of other ADEs not studied in this thesis. These include impaired cognition, 
psychomotor performance, incident frailty, admission to institutions, and risk of falls and 
fractures.  
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Sedative Load and Adverse 
Events Among Community- 
Dwelling Older People
Older people are frequent users 
of drugs with sedative properties 
although they are susceptible to 
adverse drug events. Sedative load 
refers to cumulative exposure 
to multiple drugs with sedative 
properties. This thesis investigated 
sedative load and adverse drug 
events including impaired mobility 
and muscle strength, and an 
increased risk of death among 
community-dwelling older people 
aged 75 years and older.
